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A B S T R A C T
Background
This is an updated version of an original Cochrane review published in Issue 3 2006 (Perry 2006). The review represents one from a
family of four reviews focusing on interventions for drug-using offenders. This specific review considers interventions aimed at reducing
drug use or criminal activity, or both for drug-using offenders with co-occurring mental illness.
Objectives
To assess the effectiveness of interventions for drug-using offenders with co-occurring mental illness in reducing criminal activity or
drug use, or both.
Search methods
We searched 14 electronic bibliographic databases up to May 2014 and 5 Internet resources (searched between 2004 and 11 November
2009). We contacted experts in the field for further information.
Selection criteria
We included randomised controlled trials designed to reduce, eliminate, or prevent relapse of drug use and criminal activity, or both
in drug-using offenders with co-occurring mental illness. We also reported data on the cost and cost-effectiveness of interventions.
Data collection and analysis
We used standard methodological procedures expected by The Cochrane Collaboration.
Main results
Eight trials with 2058 participants met the inclusion criteria. The methodological quality of the trials was generally difficult to rate due
to a lack of clear reporting. On most ’Risk of bias’ items, we rated the majority of studies as unclear. Overall, we could not statistically
combine the results due to the heterogenous nature of the different study interventions and comparison groups. A narrative summary of
the findings identified that the interventions reported limited success with reducing self report drug use, but did have some impact on
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re-incarceration rates, but not re-arrest. In the single comparisons, we found moderate-quality evidence that therapeutic communities
determine a reduction in re-incarceration but reported less success for outcomes of re-arrest, moderate quality of evidence and self report
drug use. Three single studies evaluating case management via a mental health drug court (very low quality of evidence), motivational
interviewing and cognitive skills (low and very low quality of evidence) and interpersonal psychotherapy (very low quality of evidence)
did not report significant reductions in criminal activity and self report drug use respectively. Quality of evidence for these three types
of interventions was low to very low. The trials reported some cost information, but it was not sufficient to be able to evaluate the cost-
effectiveness of the interventions.
Authors’ conclusions
Two of the five trials showed some promising results for the use of therapeutic communities and aftercare, but only in relation to
reducing subsequent re-incarceration. Overall, the studies showed a high degree of variation, warranting a degree of caution in the
interpretation of the magnitude of effect and direction of benefit for treatment outcomes. More evaluations are required to assess the
effectiveness of interventions for drug-using offenders with co-occurring mental health problems.
P L A I N L A N G U A G E S U M M A R Y
Interventions for drug-using offenders with co-occurring mental illness
Background
A number of policy directives are aimed at enabling people with drug problems to live healthy, crime-free lives. Drug-using offenders
with co-occurring mental health problems represent a group who access treatment for a variety of different reasons. The complexity of
the two problems makes the treatment and rehabilitation of this group particularly challenging.
Study characteristics
The review authors searched scientific databases and Internet resources to identify randomised controlled trials (where participants
are allocated at random to one of two or more treatment groups) of interventions to reduce, eliminate, or prevent relapse or criminal
activity of drug-using offenders with co-occurring mental illness. We included people of any gender, age, or ethnicity.
Key results
We identified eight trials evaluating treatments for drug-using offenderswith co-occurringmental illness. The interventions included case
management via a mental health court: a therapeutic community; an evaluation of motivational interviewing techniques and cognitive
skills (a person’s ability to process thoughts) in comparison to relaxation training; and an evaluation of interpersonal psychotherapy in
comparison to a psycho-educational intervention. Overall, the interventions reported limited success with reducing self report drug
use, but did report some success with reducing re-incarceration rates, but not re-arrest. The therapeutic community studies reported a
reduction in re-incarceration but were shown to be less effective for re-arrest and self report drug use. Three single studies evaluating
case management via a mental health drug court, motivational interviewing and cognitive skills, and interpersonal psychotherapy did
not report significant reductions in criminal activity and self report drug use respectively. Some information is provided on the costs
and cost-effectiveness of such interventions and trial evaluations focusing specifically on the needs of drug-using offenders with co-
occurring mental illness are required.
Quality of the evidence
This review was limited by the lack of information reported in this group of trials. The quality of the evidence was moderate for
therapeutic community and low to very low for the other types of intervention. The evidence is current to May 2014.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Therapeutic community for drug-using offenders with co-occurring mental illness
Patient or population: drug-using offenders with co-occurring mental illness
Settings:
Intervention: Therapeutic community
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Therapeutic community
Criminal activity - Re-ar-
rests
Follow-up: mean 12
months
117/340 (34.4%) 167/458 (36.5%) 1st study: 1.65 [0.83, 3.
28]
2nd study:0.96 [0.82, 1.
13]
798
(2 studies)
⊕⊕⊕©
moderate1
--
Criminal activity - Re-in-
carceration
Follow-up: mean 12
months
71/283 (25.1%) 47/353 (13.3%) 1st study:0.28 [0.13, 0.
63]
2nd study:0.73 [0.45, 1.
19]
3rd study:0.49 [0.27, 0.
89]
636
(3 studies)
⊕⊕⊕©
moderate2
--
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Across the 2 studies, 13 of the 18 ’Risk of bias’ items in total were rated as unclear risk; 2 of the 18 were rated as high risk.
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2 Across all the studies, 21 of the 27 ’Risk of bias’ items were rated as unclear risk; 2 of the 27 were rated as high risk.
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B A C K G R O U N D
This review is part of a family of four reviews providing a close
examination of what works in reducing drug use and criminal ac-
tivity in drug-using offenders. Overall, the four reviews contain
over 100 trials, generating a number of publications and numer-
ous comparisons (Perry 2013a; Perry 2013b; Perry 2013c). The
four reviews represent a specific interest in pharmacological in-
terventions, non-pharmacological interventions, female offenders,
and offenders with co-occurring mental illness. All four reviews
stem from an updated previous Cochrane systematic review (Perry
2006). In this set of four reviews, we consider not only the effec-
tiveness of interventions based on two key outcomes but also anal-
yse the impact of setting and intervention type.We have presented
here the revised methodology for this individual review focusing
on the impact of interventions for drug-using offenders with co-
occurring mental illness.
Description of the condition
Mental health issues in offenders are common, with over half
(64%) of jail inmates in the US reporting a serious mental ill-
ness (Glase 2006). In the US, individuals incarcerated to jails are
generally on remand awaiting trial, while those in prison have
been sentenced within the criminal justice system. One study of
mental illness in jails found that more women than men (31%
and 14.5%, respectively) have a serious mental illness (Steadman
2009). Other studies have reported that a greater proportion of
mentally ill people are arrested compared with the general popula-
tion (Lamb 1998). Factors cited as causes include a lack of support
in the community, problems accessing treatment, and the attitudes
of police and society. A systematic review evaluating 62 surveys
from 12 countries accounting for 23,000 prisoners. They found
that prisoners were several times more likely to have psychosis or
major depression and 10 times more likely to have an antisocial
personality disorder than the general population. It is unknown
how well the prison service is addressing these problems (Fazel
2002).
In the UK, renewed emphasis from Clarke’s green paper, Break-
ing the Cycle, recognises that the justice system is not always the
best place to manage the problems of less serious offenders, where
their criminal behaviour is related to their mental health prob-
lems (Clarke 2010). As a result, several diversionary schemes have
been established (Ministry of Justice 2010). The use of diversion-
ary schemes have been supported by previous systematic reviews
and meta-analytical techniques that have evaluated diversion pro-
grammes (for example mental health courts) providing a mecha-
nism for diverting individuals with severe mental illness into treat-
ment programmes instead of the prison system (Sarteschi 2011).
Findings from such studies generally show positive improvements
on a small number of clinical outcomes. However, the conclusions
are often limited by the research design (that is quasi-experimental
studies), introducing potential bias about the relative effectiveness
of such schemes. Evidence from one systematic review of serious
mentally disordered adult offenders identified seven trials, but the
evidence was insufficient to draw conclusions. The authors called
for more comparative trials to increase their confidence in the find-
ings (Fontanarosa 2013).
Description of the intervention
Many different treatments for substance misuse (for example
detoxification and therapeutic communities) have been adopted
for use in the criminal justice system. This review included any
intervention that was designed to reduce, eliminate, or prevent
relapse to drug use or criminal activity, or both. This resulted in
the inclusion of a wide range of treatments focusing on: case man-
agement via a mental health drug court, therapeutic communities,
and motivational interviewing (MI) with cognitive skills in com-
parison to relaxation training. The evidence to support the effec-
tiveness of these interventions differs and is dependent upon the
quality of the experimental evaluations employed to assess whether
they are successful in reducing drug use or criminal activity, or
both.
Case management evolved traditionally to address the needs of
prisoner re-entry programmes covering employment, education,
health, housing, and family support via assessment and connect-
ing clients with the appropriate services (Austin 1994). Case man-
agement in the US has been applied in Treatment Accountability
for Safer Communities programmes (Marlowe 2003b), and has
shown initial effectiveness but without systematic evidence in sup-
port of the process.
Previous meta-analyses and systematic reviews have shown ther-
apeutic community interventions specifically with aftercare to
have modest effects in the reduction of recidivism and drug use
(Mitchell 2012a; Pearson 1999).
Cognitive behavioural approaches, including selfmonitoring, goal
setting, self control training, interpersonal skills training, relapse
prevention, group work, and lifestyle modification, have shown
signs of success with offenders generally (Lipsey 2007), but the
evidence is based on systematic reviews that have excluded evalu-
ations focusing specifically on the needs of drug-using offenders.
Two previous systematic reviews found that motivational inter-
viewing can lead to improved retention in treatment, enhanced
motivation to change, and reduced offending, although there are
variations across studies (McMurran 2009; Smedslund 2011).
Interpersonal psychotherapy has been used in the community with
proven effectiveness in non-criminal justice settings. Such studies
have not found interpersonal psychotherapy to be superior to other
treatments (Johnson 2012).
Policy interests have also placed an increasing demand on know-
ing more about the cost and cost-effectiveness of such interven-
tions. We can draw some evidence from systematic reviews com-
pleted in the area. However, despite growing knowledge about the
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effectiveness of treatment programmes for offenders, there is no
recent systematic review evidence focusing on the effectiveness of
treatment for offenders with drugmisuse and co-occurring mental
health problems.
How the intervention might work
Interventions delivered to drug-using offenders under the care of
the criminal justice system have varied over time. Case manage-
ment is a problematic term that has been used to describe what
amounts to a range of diverse practices and supervision models
spanning several different services, including probation. These are
generally used to co-ordinate and integrate all aspects of com-
munity supervision, from the initial offender needs assessment,
through to programme delivery and the intended completion of
the order or sentencing requirement (Partridge 2004).
In the US since the 1960s therapeutic community interventions
have been used in combination with work release programmes to
rehabilitate offenders via a supportive environment over a relatively
long period. This usually encompasses the transition between the
prison and working within the community (Prendergast 2011).
The ethos of a therapeutic community intervention is to focus on
treatment on the whole self (and not on the drug abuse per se)
and the underlying symptomatic problems, where the residents
are instrumental in running the therapeutic community (Mitchell
2012a).
Cognitive behavioural approaches using programmes based on
psychological theory have been employed to try to help people
address their offending behaviour and generally have good sup-
port from the literature in their reduction of recidivism, but have
previously excluded drug-using offenders (Andrews 1990; Lipsey
1998; Lipsey 2007).
Miller and Rollnick developed motivational interviewing as a
process to motivate change in substance abusers (Miller 1991).
The technique uses different strategies such as expressing empa-
thy, avoiding arguing for change, and working on ambivalence
to strengthen commitment to change. Meta-analyses evidence
supports the use of motivational interviewing as a stand-alone
treatment and in combination with more intensive programmes
(Vasilaki 2006).
Why it is important to do this review
Many people under the care of the criminal justice system have co-
occurring mental illness and drug-misuse problems. While pre-
vious research has evaluated treatment programmes for offenders
more broadly, we know little about the challenges, treatment, and
rehabilitation opportunities for offenders with co-occurring men-
tal health and drug-misuse problems. We therefore believe that an
evaluation of existing evidence on the impact of interventions for
drug-using offenders with co-occurring mental illness might be
helpful in identifying treatments for reducing drug use and crim-
inal activity in this vulnerable population. Where possible, the re-
view will also report descriptively on the costs of such treatment
programmes.
O B J E C T I V E S
To assess the effectiveness of interventions for drug-using offenders
with co-occurring mental illness in reducing criminal activity or
drug use, or both.
The review addressed the following questions:
1. Does any treatment for drug-using offenders with co-
occurring mental illness reduce drug use?
2. Does any treatment for drug-using offenders with co-
occurring mental illness reduce criminal activity?
3. Does the treatment setting (court, community, prison/
secure establishment) affect the intervention outcome(s)?
4. Does the type of treatment affect the outcome(s)?
Additionally, this review aimed to report on the cost and cost-
effectiveness of interventions.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs).
Types of participants
We includeddrug-using offenderswith co-occurringmental illness
regardless of gender, age, or ethnicity. Drug misuse included any
study that referred to participants who used occasionally, were
dependent, or were known to abuse drugs. We defined offenders
as participants who were involved in the criminal justice system.
We judged offenders to have co-occurring mental illness where the
paper explicitly stated this. We used several different mechanisms
to identify study samples with mental health problems including:
1. use of diagnostic gold-standard tests such as the Diagnostic
and Statistical Manual of Mental Disorders, Fourth Edition
(DSM-IV) or International Statistical Classification of Diseases
and Related Health Problems, Tenth Revision (ICD-10) criteria;
or
2. the nature of the intervention (e.g. mental health court); or
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3. where the study described the participant demographic as
having a “history of psychiatric illness” or “serious mental
disorder” with a co-occurring substance misuse.
Types of interventions
Included interventions were designed, wholly or in part, to elim-
inate or prevent relapse to drug use or criminal activity, or both,
among participants. We defined ’relapse’ as participants who may
have returned to an incarcerated setting or were subsequently ar-
rested, or who had relapsed back into drug misuse, or both. We
included a range of different types of interventions in the review.
Experimental interventions included in the review
1. Any pharmacological intervention (e.g. buprenorphine,
methadone)
2. Any psychosocial intervention (e.g. therapeutic community,
case management, cognitive behavioural therapy, interpersonal
psychotherapy, motivational interviewing)
Control interventions included in the review
1. No treatment
2. Minimal treatment
3. Waiting list
4. Treatment as usual
5. Other treatment
Types of outcome measures
Primary outcomes
For the purpose of this review, we categorised our primary out-
comes into those relating to dichotomous and continuous drug
use or criminal activity, or both. Where papers reported a number
of different follow-up periods, we reported the longest period, as
we felt this measure was the most conservative estimate of effec-
tiveness.
1. Drug use measures reported as:
i) self report drug use (unspecified drug, specific drug
use not including alcohol, Addiction Severity Index composite
scores);
ii) biological drug use (measured by drugs testing by
either urine or hair analysis).
2. Criminal activity as measured by:
i) self report or official report of criminal activity
(including arrest for any offence, drug offences, re-incarceration,
convictions, charges, and recidivism).
Secondary outcomes
Our secondary outcome reported on cost or cost-effectiveness
information. We used a descriptive narrative to describe these
findings. We undertook a full critical appraisal based on the
Drummond 1997 checklist for studies presenting sufficient infor-
mation.
Search methods for identification of studies
Electronic searches
The update searches identified records from 2004 to May 2014.
• CENTRAL (issue 5, 2014) (Appendix 1)
• MEDLINE (1966 to May 2014) (Appendix 2)
• EMBASE (1980 to May 2014) (Appendix 3)
• PsycINFO (1978 to April 2014) (Appendix 4)
• PASCAL (1973 to November 2004)a (Appendix 5)
• SciSearch (Science Citation Index) (1974 to April 2014)
(Appendix 5)
• Social SciSearch (Social Science Citation Index) (1972 to
April 2014) (Appendix 5)
• ASSIA (1987 to April 2014) (Appendix 6)
• Wilson Applied Science and Technology Abstracts (1983 to
October 2004)a
• Inside Conferences (1993 to November 2004)a
• Dissertation Abstracts (1961 to October 2004)a
• NTIS (1964 to April 2014)
• Sociological Abstracts (1963 to April 2014) (Appendix 7)
• HMIC (2004 to April 2014) (Appendix 8)
• PAIS (1972 to April 2014) (Appendix 9)
• SIGLE (1980 to June 2004)b (Appendix 10)
• Criminal Justice Abstracts (1968 to April 2014) (Appendix
11)
• LILACS (2004 to April 2014)
• National Research Register (March 2004)c (Appendix 12)
• Current Controlled Trials (December 2009)
• DrugScope (February 2004) - unable to access
• SPECTRA (March 2004)d (Appendix 13)
aUnable to access further to 2004 search.
bDatabase not updated since original 2004 search.
cNo longer exists.
dNow Campbell Collaboration searched online.
In our update of the original reviewwe restricted the search strategy
to studies that were published or unpublished from 2004 onwards
(Perry 2006). We did not search several of the original databases
for this update (indicated by the key at the end of the database
list). We did not search PASCAL, ASSIA,Wilson Applied Science
and Technology Abstracts, Inside Conferences, and Dissertation
Abstracts, as these databases were available only via the fee-charg-
ing Dialog online host service, and we did not have the required
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resources. The National Research Register no longer exists, and
SIGLE has not been updated since 2005. DrugScope is available
only to subscribing members. The original searches were under-
taken by DrugScope employees.
We developed search strategies for each database to employ the
search engine most effectively and to make use of any controlled
vocabulary. We designed search strategies to restrict the results to
RCTs and placed no language restrictions. We included method-
ological search filters designed to identify trials. Whenever possi-
ble, we used filters retrieved from the InterTASC Information Spe-
cialists’ Sub-Group Search Filter Resource site (www.york.ac.uk/
inst/crd/intertasc/). If filters were unavailable from this site, we
used search terms based on existing filters instead.
In addition to the electronic databases, we searched relevant web-
sites (Home Office, National Institute of Drug Abuse, and Euro-
pean Association of Libraries and Information Services on Alcohol
and Other Drugs). We searched directory websites up to Novem-
ber 2011. We placed no language restrictions on identification and
inclusion of studies in the review.
We have listed details of the update search strategies and results
and websites searched in Appendix 1; Appendix 2; Appendix 3;
Appendix 4; Appendix 5; Appendix 6; Appendix 7; Appendix 8;
Appendix 9; Appendix 10; Appendix 11; Appendix 12; Appendix
13.
Searching other resources
Reference checking
We scrutinised the reference lists of all retrieved articles for addi-
tional references and searched the catalogues of relevant organisa-
tions.
Personal communication
We sought out experts for their knowledge of other published or
unpublished studies relevant to the review.
Data collection and analysis
Selection of studies
Two review authors independently inspected titles and abstracts
identified by the search strategy. We obtained each potentially rel-
evant study as a full article, and two review authors independently
assessed these for inclusion. In the case of discordance, a third re-
view author arbitrated. One review author undertook translation
of articles not written in the English language.
We divided the screening process into two key phases. Phase one
used the initial eight key questions reported in the original review
(Perry 2006).
Phase one pre-screening criteria:
1. Is the document an empirical study? [If no, exclude
document]
2. Does the study evaluate an intervention, a component of
which is designed to reduce, eliminate, or prevent relapse in
drug-using offenders?
3. Are the participants referred by the criminal justice system
at baseline?
4. Does the study report pre- and post-programme measures
of drug use?
5. Does the study report pre- and post-programme measures
of criminal behaviour?
6. Is the study an RCT?
7. Do the outcome measures refer to the same length of
follow-up for two groups?
Following identification of relevant papers from phase one, we
sought in phase two screening to identify those papers describing
offenders with a mental illness. This information was primarily
obtained from the participant description and the type of inter-
vention (for example mental health drug court).
Phase two pre-screening:
1. Is the study population comprised wholly of participants
with diagnosed mental illness using DSM-IV or ICD-10
diagnostic criteria? [if yes, include document]
2. Is the study population comprised wholly of participants
identified on screening to have a mental health problem(s) based
on intervention eligibility (e.g. mental health court)? [if yes,
include document]
3. Where the full study population is not comprised of
offenders with diagnosed or presumed mental illness, are separate
results given for those participants with mental illness? [if no,
exclude document]
Drug-using interventions were implied if the programme was tar-
geted at reducing drug use in a group of individuals or could be
ascertained from the background characteristics of the group. Of-
fenders were individuals residing in special hospitals, prisons, the
community, or who were diverted from court or placed on arrest
referral schemes for treatment. We did accept papers in the review
where the entire sample were not using drugs, but reported pre
and post measures needed to be the same at both time points. The
study setting could change throughout the process of the study.
For example, offenders could begin in prison but progress through
a work release project into a community setting. Finally, studies
did not need to report both drug and criminal activity outcomes.
If either of these were reported, we included the study in the re-
view.
Data extraction and management
We used data extraction forms to standardise the reporting of
data from all studies obtained as potentially relevant. Two review
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authors independently extracted data and subsequently checked
them for agreement.
Assessment of risk of bias in included studies
Three review authors (AEP, MMSJ, RW) independently assessed
risk of bias of all included studies using the ’Risk of bias’ assessment
criteria recommended in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011).
The recommended approach for assessing risk of bias in studies
included in Cochrane reviews is a two-part tool, addressing seven
specific domains, namely sequence generation and allocation con-
cealment (selection bias), blinding of participants and providers
(performance bias), blinding of outcome assessor (detection bias),
incomplete outcome data (attrition bias), selective outcome re-
porting (reporting bias), and other source of bias. The first part
of the tool involves describing what was reported to have hap-
pened in the study. The second part of the tool involves assigning
a judgement relating to the risk of bias for that entry, in terms of
low, high, or unclear risk. To make these judgements, we used the
criteria indicated by theCochrane Handbook for Systematic Reviews
of Interventions adapted to the addiction field. See Appendix 14
for details.
The domains of sequence generation and allocation concealment
(avoidance of selection bias) were addressed in the tool by a single
entry for each study.
Blinding of participants, personnel, and outcome assessor (avoid-
ance of performance bias and detection bias) were considered sep-
arately for objective outcomes (for example drop-out, use of sub-
stance of abuse measured by urine analysis, participants relapsed at
the end of follow-up, participants engaged in further treatments)
and subjective outcomes (for example duration and severity of
signs and symptoms of withdrawal, participant self reported use of
substance, side effects, social functioning as integration at school
or at work, family relationship).
Incomplete outcome data (avoidance of attrition bias) was con-
sidered for all outcomes except for drop-out from the treatment,
which is very often the primary outcome measure in trials on ad-
diction.
For studies identified in the search, the review authors attempted
to contact study authors to establish whether a study protocol was
available.
Measures of treatment effect
The mean differences (MD) were used for outcomes measured
on the same scale and the standardised mean difference (SMD)
was used for outcomes measured on different scales. Higher scores
for continuous measures are representative of greater harm. We
presented dichotomous outcomes as risk ratios (RR), with 95%
confidence intervals (CIs).
Unit of analysis issues
To avoid double counting of outcomemeasures (for example arrest
and parole violation) and follow-up time periods (for example 12,
18 months), we checked all trials to ensure that multiple studies
reporting the same evaluation did not contribute towards mul-
tiple estimates of program effectiveness. We followed Cochrane
guidance, and where appropriate we combined intervention and
control groups to create a single pair-wise comparison. Where this
was not appropriate, we selected one treatment arm and excluded
the others.
Dealing with missing data
We attempted to contact study authors via email where missing
data occurred in the original publication.
Assessment of heterogeneity
We assessed heterogeneity using the I² statistic and Chi² statistic
(Higgins 2011).
Data synthesis
We planned to use the RevMan software package to perform a
series of meta-analyses for continuous and dichotomous outcome
measures (RevMan 2012). We planned to use a random-effects
model to account for the fact that participants did not come from
a single underlying population. Because of the high heterogeneity
of included studies for types of intervention compared, no meta-
analysis were performed. The narrative tables included a presen-
tation of the study details (for example author, year of publica-
tion, and country of study origin), study methods (for example
random assignment), participants (for example number in sample,
age, gender, ethnicity, age, mental health status), interventions (for
example description, duration, intensity, and setting), outcomes
(for example description, follow-up period, and reporting mech-
anism), resource and cost information and resource savings (for
example number of staff, intervention delivery, estimated costs,
and estimated savings) and notes (for examplemethodological and
quality assessment information).
Subgroup analysis and investigation of heterogeneity
Wehad planned to conduct sensitivity analyses to assess the impact
of studies at high risk of bias compared with those at low or unclear
risk of bias. Because of the overall high risk of bias of the included
studies, this analysis was not possible.
R E S U L T S
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Description of studies
Results of the search
Original review
The original searches spanned from database inception toOctober
2004. They identified a total of 8217 records after duplication.We
acquired a total of 90 full-text papers for assessment and excluded
36 papers, bringing 24 trials to the review (see Figure 1).
Figure 1. Study flow diagram of paper selection process: Original Review
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First update
The updated searches spanned from October 2004 until March
2013. These identified a total of 3896 records after duplication.
We acquired a total of 109 full-text papers for assessment and
excluded 104 papers, bringing 5 new trials to the review (see Figure
2).
Figure 2. Study flow diagram of paper selection process: First update
Second update
The updated searches spanned fromMarch 2013 until April 2014.
These identified a total of 2092 records after duplication. We
acquired a total of 72 full-text papers for assessment and excluded
69 papers, bringing 3 new trials to the review, making a total of
14 publications represented by 8 trials (see Figure 3).
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Figure 3. Study flow diagram of paper selection process: Second update
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Included studies
Fourteen publications represented eight trials published between
1999 and 2014. The eight trials consisted of three singular trial
publications on different interventions, Cosden 2003, Sacks 2011,
and Stein 2011, and two trials represented by five publications.
The first trial represented an evaluation of one intervention to two
comparison groups, using different outcomemeasures (drug use at
12 months reported by Sacks 2004). The second trial represented
three publications and four comparisons presenting follow-up data
successively between 12 and 60 months (Wexler 1999).
Treatment regimens and settings
Six studies were conducted in a secure setting. The evaluations
considered a therapeutic community intervention and aftercare in
comparison to some alternative-sentencing option (Johnson 2012;
Lanza 2013; Sacks 2004; Sacks 2008; Sacks 2011; Wexler 1999).
Two studies were conducted in a court setting. The evaluations
compared assertive case management versus treatment as usual
in a mental health drug court (Cosden 2003), and motivational
interviewing with relaxation training in a group of adolescents
with significant depression (Stein 2011).
No studies assessed the efficacy of pharmacological treatments.
No studies were identified in the community.
Countries in which the studies were conducted
All the studies were published in the US.
Duration of trials
The trial duration varied between 3months’ follow-up, in Johnson
2012, Lanza 2013, and Stein 2011, to a 5-year follow-up (Wexler
1999). The remaining studies reported on outcomes at 12, 24, and
36 months (Cosden 2003; Sacks 2011; Sacks 2008; Sacks 2004).
Participants
Seven of the eight comparisons included adult drug-using offend-
ers. One study investigated the impact of motivational interview-
ing in adolescents aged 14 to 19 years (Stein 2011).
Three studies included female offenders (Cosden 2003; Johnson
2012; Stein 2011). Adult male offenders were the focus of the
study populations in the majority of studies, with a mean age of
30 years.
In all study populations, themajority of participants were of white
ethnic origin.
Mental health diagnoses varied across the studies (see Table 1 for
more information).
Excluded studies
We excluded 172 studies. (See Characteristics of excluded studies
for further details.) Reasons for exclusion were: lack of criminal
justice involvement in referral to the intervention; not reporting
relevant drug or crime outcome measures or both at both the pre-
and post-intervention periods; and allocation of participants to
study groups that were not strictly randomised or did not con-
tain original trial data. We excluded the majority of studies be-
cause the study population were not offenders. We excluded one
study because follow-up periods were not equivalent across study
groups (Di Nitto 2002), and another because the study interven-
tion (acupuncture) did not measure our specified outcomes of
drug use or criminal activity (Berman 2004). One study reported
the protocol of a trial only (Baldus 2011), while another only con-
tained conference proceedings (Kinlock 2009). For one trial, we
were unable to obtain the data (Cogswell 2011), and for another
we were unable to obtain the full-text version (Rowan-Szal 2005).
Risk of bias in included studies
Allocation
Randomisation
All of the nine included comparisons were described as ran-
domised. Five of the included studies reported on how the ran-
domisation sequence was generated and were judged as at low risk
of bias (Cosden 2003; Johnson 2012; Lanza 2013; Sacks 2011;
Stein 2011). The remaining three studies did not report how
the randomisation sequence of participants was generated (Sacks
2004; Sacks 2008; Wexler 1999).
Characteristics at baseline
Five of the eight studies were similar on drug use at baseline (
Johnson 2012; Sacks 2004; Sacks 2008; Sacks 2011; Stein 2011),
two studies were rated unclear (Cosden 2003; Lanza 2013), and
one study showed comparable baseline differences (Sacks 2004).
For similarity on criminal justice measures, six studies were rated
as similar (Cosden 2003; Johnson 2012; Sacks 2008; Sacks 2011;
Sacks 2004; Stein 2011; Wexler 1999), and two were rated as
unclear (Lanza 2013; Stein 2011).
Allocation concealment
Of the eight studies, only one adequately reported that the alloca-
tion process was concealed (Johnson 2012).
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Blinding
We assessed blinding across four dimensions considering perfor-
mance and detection bias across subjective and objective measures
(see Appendix 14). For five of the eight studies, we considered
blinding unclear on all four measures of blinding (Sacks 2004;
Sacks 2008; Stein 2011; Wexler 1999). We rated one study as at
high risk of bias on two of the four measures (Cosden 2003), and
we rated another study as at low risk of bias across three of the
four domains (Lanza 2013).
Incomplete outcome data
Loss to follow-up was reported to differing extents in the included
studies. We rated two studies as at low risk of bias (Cosden 2003;
Sacks 2008), and we rated four as at low risk with limited attrition
noted (Johnson 2012; Lanza 2013; Sacks 2004;Wexler 1999).We
rated two studies as unclear (Sacks 2011; Stein 2011).
Selective reporting
We rated five of the eight trials as unclear (Cosden 2003; Sacks
2004; Sacks 2011; Stein 2011;Wexler 1999).We rated two studies
as at low risk (Lanza 2013; Sacks 2008), and we rated one study
as at high risk (Johnson 2012).
Other potential sources of bias
Of the eight studies, we rated four as at high risk of other bias
(Cosden 2003; Johnson 2012; Stein 2011; Wexler 1999), three
as at low risk with no further concerns (Lanza 2013; Sacks 2008;
Sacks 2011), and the final study as unclear (Sacks 2004).
See Figure 4 and Figure 5 for more details.
Figure 4. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 5. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Effects of interventions
See: Summary of findings for themain comparisonTherapeutic
community for drug-using offenders with co-occurring mental
illness;Summary of findings 2Mental health court for drug-using
offenders with co-occurring mental illness; Summary of findings
3 Motivational interviewing and cognitive skills for drug-using
offenders with co-occurring mental illness; Summary of findings
4 Interpersonal psychotherapy for drug-using offenders with co-
occurring mental illness
We considered each of our studies in relation to the key objectives
of the review and grouped them together by outcome measures
and individual intervention type (see Table 2 formore details). We
have summarised the main comparisons in Summary of findings
for the main comparison; Summary of findings 2.
Due to high heterogeneity of the interventions compared in the
included studies, it was not possible to combine study results, and
we performednometa-analyses for drugusemeasures and criminal
activities. Furthermore as all the included studies were conducted
in a secure or court setting, it was not possible to combine study
results, and we performed no meta-analyses.
1. Therapeutic community and aftercare versus treatment
as usual
See Summary of findings for the main comparison
Impact on self report drug use
Three studies reported results about self report drug use. One
study found statistically significant reduction: Sacks 2004 (RR
0.58, 95% CI 0.36 to 0.93, 139 participants); the second study
found nearly statistically significant reduction: Sacks 2008 (RR
0.73, 95% CI 0.53 to 1.01, 370 participants); while the third
study found no statistically significant reduction: Wexler 1999
(RR 1.11, 95% CI 0.82 to 1.49, 576 participants).
Impact on criminal activity
Two studies reported no statistically significant reduction in re-
arrest following treatment: Sacks 2008 (RR 1.65, 95% CI 0.83
to 3.28, 370 participants); and Wexler 1999 comparing a secure
establishment-based therapeutic community program versus no
treatment (RR 0.96, 95% CI 0.82 to 1.13, 428 participants),
moderate quality of evidence; see Analysis 1.1
Three studies evaluated the impact of therapeutic community
treatment using re-incarceration measures. Two studies reported
statistically significant reduction: Sacks 2004 comparing Personal
Reflections therapeutic community and voluntary residential af-
tercare versusmental health programme (RR0.28, 95%CI 0.13 to
0.63, 139 participants); and Sacks 2011 comparing re-entry mod-
ified therapeutic community treatment versus parole supervision
case management (RR 0.49, 95% CI 0.27 to 0.89, 127 partici-
pants). One study did not find statistically significant results: Sacks
2008 comparing a therapeutic community program versus cog-
nitive behavioural intervention (RR 0.73, 95% CI 0.45 to 1.19,
370 participants), moderate quality of evidence, see Analysis 1.1
2. Mental health court and case management versus
treatment as usual (standard court proceedings)
SeeSummary of findings 2
Impact on self report drug use
The study did not assess this outcome.
Impact on self report criminal activity
One study reported no statistically significant reduction in crim-
inal activity: RR 1.05, 95% CI 0.90 to 1.22, 235 participants
(Cosden 2003), very low quality of evidence, see Analysis 2.1
3. Motivational interviewing and cognitive skills versus
relaxation therapy
SeeSummary of findings 3
Impact on self report drug use--continuous
One study reported no statistically significant reduction in self re-
port drug use: MD -7.42, 95% CI -20.12 to 5.28, 162 partici-
pants (Stein 2011), low quality of evidence, see Analysis 3.1
Impact on self report drug use--dichotomous
One study reported no statistically significant reduction in self
report drug use: RR 0.92, 95% CI 0.36 to 2.33, 41 participants
(Lanza 2013), very low quality of evidence, see Analysis 3.2
Impact on self report criminal activity
The studies did not assess this outcome.
4. Interpersonal psychotherapy versus a psycho-educational
intervention
See Summary of findings 4
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Impact on self report drug use
One study reported no statistically significant reduction in self
report drug use: RR 0.67, 95% CI 0.30 to 1.50, 38 participants
(Johnson 2012), very low quality of evidence, see Analysis 4.1
Impact on self report criminal activity
The studies did not assess this outcome.
Cost and cost-effectiveness
Four papers referred to the costs or cost-effectiveness of the thera-
peutic community programmes. The Sacks 2011 paper suggested
that cost-beneficial analyses associated with each intervention in
achieving the desired outcomewould greatly assist howbest to allo-
cate scarce resources. The Prendergast five-year evaluation presents
economic differences when compared to the one-year Amity out-
come study. The Prendergast research suggests that optimal cost
savings appear to require prison treatment plus aftercare rather
than prison treatment alone (McCollister 2013). One study con-
tained some information about cost, but not sufficient to con-
duct a cost-effectiveness appraisal (Sacks 2004). The authors of
this study noted that the additional marginal costs on top of the
specific incarceration costs were USD7.37 per day, compared with
the USD148.19 cost of a prison day. This suggests a substantial
cost saving of using therapeutic community programmes as op-
posed to prison.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Mental health court for drug-using offenders with co-occurring mental illness
Patient or population: drug-using offenders with co-occurring mental illness
Settings:
Intervention: Mental health court
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Mental health court
Self report dichotomous
criminal activity
Follow-up: mean 12
months
Study population RR 1.05
(0.9 to 1.22)
208
(1 study)
⊕©©©
very low1,2
--
724 per 1000 761 per 1000
(652 to 884)
Moderate
725 per 1000 761 per 1000
(652 to 885)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 4 of the 9 items were rated as high risk; 4 of the 9 items were rated as unclear risk.
2 Only 1 study with 208 participants
1
8
In
te
rv
e
n
tio
n
s
fo
r
d
ru
g
-u
sin
g
o
ffe
n
d
e
rs
w
ith
c
o
-o
c
c
u
rrin
g
m
e
n
ta
l
illn
e
ss
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
5
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Motivational interviewing and cognitive skills for drug-using offenders with co-occurring mental illness
Patient or population: drug-using offenders with co-occurring mental illness
Settings:
Intervention: Motivational interviewing and cognitive skills
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Motivational interview-
ing and cognitive skills
Self report drug use con-
tinuous
Follow-up: mean 3
months
-- The mean self report drug
use continuous in the in-
tervention groups was
7.42 lower
(20.12 lower to 5.28
higher)
-- 162
(1 study)
⊕⊕©©
low1,2
--
Self report drug use di-
chotomous
Follow-up: mean 3
months
Study population RR 0.92
(0.36 to 2.33)
41
(1 study)
⊕©©©
very low3,4
--
364 per 1000 335 per 1000
(131 to 847)
Moderate
364 per 1000 335 per 1000
(131 to 848)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio
1
9
In
te
rv
e
n
tio
n
s
fo
r
d
ru
g
-u
sin
g
o
ffe
n
d
e
rs
w
ith
c
o
-o
c
c
u
rrin
g
m
e
n
ta
l
illn
e
ss
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
5
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 1 of 9 items judged as high risk; 7 of 9 items judged as unclear risk.
2 Only 1 study with 162 participants.
3 3 of 9 items rated as high risk; 1 of 9 rated as unclear risk.
4 Only 1 study with 41 participants.
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Interpersonal psychotherapy for drug-using offenders with co-occurring mental illness
Patient or population: drug-using offenders with co-occurring mental illness
Settings:
Intervention: Interpersonal psychotherapy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Interpersonal
psychotherapy
Self report drug use di-
chotomous
Follow-up: mean 3
months
Study population RR 0.67
(0.3 to 1.5)
38
(1 study)
⊕©©©
very low1,2
474 per 1000 317 per 1000
(142 to 711)
Moderate
474 per 1000 318 per 1000
(142 to 711)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 2 of 9 items rated as high risk; 2 of 9 items rated as unclear risk.
2 Only 1 study with 38 participants.
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D I S C U S S I O N
Summary of main results
This systematic review provided evidence from eight trials. The
trials were conducted in secure settings and the court judicial sys-
tem. We did not identify any studies that evaluated interventions
for drug-using offenders with co-occurring mental illness in the
community who were on parole or under the care of the proba-
tion service.We therefore do not know whether such interventions
work better in one setting as opposed to another. Four different
types of treatment interventions were classified across the studies.
These were divided into: case management via a mental health
drug court, therapeutic community treatment, motivational in-
terviewing with cognitive skills in comparison to relaxation train-
ing, and interpersonal psychotherapy in comparison to a psycho-
educational intervention. The therapeutic community studies re-
ported statistically significant reductions in subsequent re-incar-
ceration, but not for re-arrest. This finding supports previous re-
search that demonstrates that the combinationof therapeutic com-
munity treatment and aftercare release seem to produce the most
consistent and successful results Mitchell 2012a. Though not ad-
dressed within this review, those clients also remained in treatment
for the longest period appeared to benefit the most (Sacks 2004).
One of the included studies was specifically adapted therapeutic
community treatment for women offenders. This study compared
women assigned to therapeutic community treatment or standard
treatment, a cognitive behavioural recovery and relapse preven-
tion curriculum referred to in the system as the Intensive Outpa-
tient Program (Sacks 2008). At six months the study found that
both groups improved significantly on variables of mental health,
substance use, criminal behaviour, and HIV risk. The authors
note that further exploration of each model for different offender
groups is required to permit a more precise utility of each model.
The authors conclude that these preliminary findings suggest the
importance of providing gender-specific sensitive and comprehen-
sive approaches within the correctional system to respond to the
complex substance abuse needs of female offenders (Sacks 2008).
The more recent follow-up study investigated outcomes at 6 and
12 months. The outcomes followed a similar pattern, with both
groups of women benefiting from treatment. Therapeutic com-
munity treatment was found to be more beneficial than cogni-
tive behavioural therapy at improving re-incarceration rates and
lengthening the amount of time spent in the community before
subsequent re-incarceration (Sacks 2008).
Wenotedno statistically significant reductions for criminal activity
or self report drug use with the use of case management via a men-
tal health court; motivational interviewing with cognitive skills
over relaxation training; and acceptance and commitment ther-
apy (ACT)or interpersonal psychotherapy (Cosden 2003; Johnson
2012; Lanza 2013; Stein 2011). The interpersonal psychotherapy
was evaluated using a pilot study of women suffering from ma-
jor depression and substance use disorder (Johnson 2012). This
study is primarily a feasibility study to assess the applicability of
using interpersonal psychotherapy in a prison environment.While
small, it is in fact one of the largest trials including women with
co-occurring substance misuse and mental health problems. The
findings showed that participants undergoing interpersonal psy-
chotherapy had significantly reduced levels of depression and sub-
stance misuse over the attention-matched control. The study eval-
uating ACT in comparison to traditional cognitive behavioural
therapy found higher levels of abstinence in the ACT (43.8%)
when compared to the control (18.2%). These findings are similar
to other studies that have used ACT albeit in non-incarcerated
populations (Hayes 2004). The authors attribute the success of
ACT to the nature of the ’co-joint’ work between the therapist and
client, the aim of which is to increase the flexibility and structure
of the therapy allowing the client to have greater autonomy over
decision-making. They argue that cognitive behavioural therapy
is in contrast more systematically directed by the therapist, leaving
little scope for responsive change (Lanza 2013). In summary, the
studies varied greatly in nature, and given that they represent a
series of singular trials, caution is called for in interpreting their
results.
The impact on criminal-activity outcomemeasures varied, and the
differences noted between the reductions in re-incarceration but
not re-arrest could be a reflection of the measurement processes.
For example, incarceration to prison is a longer process involving
a court case, and as a numerical outcome measure is less likely
to be recorded within the time frame of an experimental evalua-
tion. In comparison, ’arrest’ as a measurement outcome is more
frequent and is recorded in the criminal justice system within a
shorter time frame. Sacks 2011 also argues that participation in
different treatment options does not necessarily lead to less in-
volvement with the criminal justice system, but that the sever-
ity of the offences are reduced such that re-incarceration is less
likely. The follow-up studies to the Wexler trial also commented
on differential effectiveness of treatment outcomes (Prendergast
2003; Prendergast 2004). The authors argue that focusing on only
one or two outcomes may mask the impact of treatment on other
outcome domains that are of interest to various stakeholders. For
example, measuring re-arrest or re-incarceration does not reveal
the reason for why an individual has returned to correctional su-
pervision. Questions that remain unanswered through such mea-
surement include (i) the length of time an offender remains in the
community until re-arrest, (ii) knowledge about what crimes are
committed, and (iii) the reasons for return.
In terms of addressing some of the complex issues of individu-
als with mental illness and co-occurring substance abuse, the evi-
dence from this systematic reviewprovides little information.Only
three studies discussed the differential treatment effects on the
severity of depression (Cosden 2003; Johnson 2012; Stein 2011).
The Cosden 2003 study noted that further understanding of how
to help clients with serious mental illness with different levels of
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treatment is needed. The Johnson 2012 study noted that partic-
ipants undergoing interpersonal psychotherapy had significantly
reduced levels of depression and substance misuse over the at-
tention-matched control. The authors noted that the intensity of
treatment delivered once the individual is released into the com-
munity is key to maintaining good outcomes. However, they go
on to state that women often experience delays in treatment and
service provision on release, and they suggest that alternative ser-
vice provision such as phone treatment might be helpful in pro-
viding a more intensive post-release treatment and useful in times
of crisis.
Several successful treatment elements were reported throughout
the five trials with a number of key themes identified. First, we
noted the issue of treatment engagement as important. In themen-
tal health court trial, the informal support from family and friends
encouraged the engagement of clients within the community to
longer term gain (Cosden 2003). Second, programmes that were
specifically adapted to the needs of mental health clients tended to
include a cognitive behavioural curriculum that emphasised crim-
inal thinking and behaviour alongside psycho-educational classes.
The focus of combining these two types of mechanisms is to en-
hance an individuals ability to recognise and understand their sub-
stance misuse and mental health problems in more detail (Sacks
2004). Third, the longer an individual is engaged in treatment the
better the outcome(s) (Wexler 1999).
Overall completeness and applicability of
evidence
General applicability
The applicability of the evidence is hindered in general by the lack
of trials covering a range of different treatment options for drug-
using offenders with co-occurring mental illness. As the trials were
conducted in the US judicial system, they are, therefore, limited in
their generalisation to other criminal justice systems outside of the
US. The current evidence suggests that therapeutic community
treatment may have some effect in reducing re-incarceration rates,
but we do not know how such treatment facilitates the specific re-
habilitation requirements of drug-using offenders with co-occur-
ring mental illness, and the studies represent singular outcomes.
For drug use measures, the review only reports on self report drug
use, as not enough information using biological outcomemeasures
of drug use (for example hair and urine analysis) was available.
As a result, the self report information must be interpreted with
caution. In addition, we can say nothing about whether the treat-
ments are effective in reducing drug use and subsequent criminal
behaviour while offenders are on parole or on probation in the
community.
Mental health information
Although the review specifically sought to identify studies includ-
ing participants with co-occurring mental illness, the study de-
scriptions of mental ill health varied (see Table 1). The Cosden
2003 study used a psychiatrist or psychologist to conduct a clinical
interview to make a mental health diagnosis alongside substance
misuse. This resulted in a mental health court sample of individ-
uals diagnosed with a range of mental health problems including
mood disorder, schizophrenia, bipolar disorder, and dual diagno-
sis. Other papers referred to use of the DSM-IV diagnostic criteria
(Sacks 2011), but subsequently provided little information with
regards to individual mental illness needs. Demographic informa-
tion in the Sacks study reported on other aspects of mental health
prognosis, including lifetime mental health treatment, lifetime in
patient care, and prescribed medication (Sacks 2004). TheWexler
1999 series of studies reported a range of diagnoses, including
antisocial personality disorder, phobias, post-traumatic stress dis-
order, depression, dysthymia, and attention deficit disorder, but
did not describe how these diagnoses were confirmed or assessed
within the population.
Six of the eight trials reported on change in mental health well-
being. Three trials reported on used of the Beck Depression In-
ventory, Global Severity Index, and the Posttraumatic Diagnostic
Scale (Sacks 2004; Sacks 2008; Sacks 2011) Another study re-
ported on depression but used the Hamilton Rating Scale for De-
pression (Johnson 2012). Two studies reported presence of mood
disorder alongside schizophrenia, general anxiety disorder, and an-
tisocial personality disorder (Cosden 2003; Lanza 2013). Future
updates of this review will include mental health outcomes in or-
der to assess the impact of treatment on mental health well-being
alongside criminality and drug use.
Cost information
Cost information within the studies was lacking, allowing for little
comparison of cost-effectiveness between different types of drug
treatment programmes. Regular report of effect sizes would aid
calculations for power analysis and provide estimates of the mag-
nitude of treatment effect needed for cost-benefit and cost-effec-
tiveness analysis.
Quality of the evidence
Overall, the ’Risk of bias’ assessment was limited due to lack of
information reported in the trials. We therefore rated most of the
studies on the majority of ’Risk of bias’ measures as unclear. The
main limiting factor was the lack of reporting evidence, which
prevented the reviewer authors from making a clear judgement
of bias. Since the imprecision of reporting lowers the quality of
evidence, this means that further research is very likely to have an
important impact on our confidence in the estimate of effect and
is likely to change the estimate. In addition, a number of specific
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limitations were described relating to the study design (and lead-
ing to problems of selection bias), and sample sizes were small.
The Stein 2011 study was noted as being relatively underpowered.
Replication of the study is required to enhance the generalisation
and external validity of the study findings. Similar modest sample
sizes were reported by Sacks 2011 and Cosden 2003, who sug-
gested that larger samples should be used to provide a more precise
estimate of effect. The Cosden 2003 study also reported on the
possibility of outcome bias, as the interviewer was not blind to the
outcome condition of the participant, and loss to follow-up (25%
of the study sample were lost to follow-up) at 12 months.
Another possible selection bias concern in the series of Wexler
studies was that participants were randomly assigned to the prison
therapeutic community treatment and regular prison conditions
but not to aftercare (Wexler 1999; Prendergast 2003; Prendergast
2004). The authors noted that possible differences in personal
motivation may account for some of the positive outcomes asso-
ciated with participants’ continued support for aftercare services.
Subsequently these participants were noted as having the highest
’readiness scores’, which suggests that motivation creates an im-
portant consideration on client selection (Wexler 1999).
Overall the quality of evidence was judged as moderate for ther-
apeutic community and low to very low for mental health court,
motivational interviewing, and interpersonal psychotherapy.
Potential biases in the review process
Besides the limitations associated with the literature, there are also
two limitations of the review methodology. Specifically, the orig-
inal review included an additional five fee-paying databases and
one search using DrugScope. In this current review, resources did
not allow such extensive searching. While the electronic database
searches were updated to April 2014, the website information has
only been updated to November 2011. As a result, the literature
will require further extensive searching when the review is next
updated.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review highlights the paucity of evidence for drug-using of-
fenders with co-occurring mental illness. Two of the five trials
showed some promising results for the use of therapeutic commu-
nity and aftercare, but only in relation to reducing subsequent re-
incarceration. Overall, the studies showed a high degree of varia-
tion, warranting a degree of caution in the interpretation of the
magnitude of effect and direction of benefit for treatment out-
comes. More evaluations are required to assess the effectiveness of
interventions for drug-using offenders with co-occurring mental
illness.
Implications for research
We have identified several research implications:
1. Good-quality research is required to evaluate the effectiveness
of interventions in offenders with substance misuse problems and
co-occurring mental illness. Of particular interest is the extended
long-term effects of aftercare and the level of contact required
with services in the community. Further research to enhance to
explore the intensity of different community treatment alternatives
following release may help to unravel this process.
2. Better descriptions of participants’ mental health problems and
more detailed information about mental health diagnoses are re-
quired to enable the transferability of information to clinical prac-
tice. Such information could also facilitate the use of mental health
diagnoses as a moderator within the analysis of the outcomes.
3. Trial interventions specifically focusing on females and adoles-
cents are required. In the current review, only one study contained
females, and one study reported on adolescents with depression.
4. Little is known about the interaction between mental illness,
individual personal characteristics and positive outcomes relating
to treatment success. In terms of depression, Stein 2011 attempted
to explore some of the differences between participants with few
and with many depressive symptoms. Future studies should con-
sider an analysis of existing datasets which might reveal which in-
dividuals with which mental health diagnosis fair better than oth-
ers. This would reveal who might potentially benefit most from
treatment and enable the appropriate targeting of resources.
5. Standardising cost and cost-effectiveness information within
trial evaluations would help policymakers make decisions about
health versus criminal justice costs. New outcome evaluations
should consider the length of time to a parolee’s re-arrest or re-
incarceration, as this has cost implications. For example, the Pren-
dergast 2003/4 study found that community residential treatment
kept parolees from relapse or recidivism so long as they remained in
treatment topping treatment (prior to the intended dose) tended
to lead to relapse or recidivism rates equivalent to participants who
received prison treatment only (Prendergast 2003; Prendergast
2004). Such evaluations provide potential important information
for stakeholders and funding bodies involved in distributing bud-
gets to fund such enterprises.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Cosden 2003
Methods Allocation: random assignment
Randomisation method: adequate/low risk
Similar on drug use: unknown/unclear risk
Similar on criminal activity: yes
Blinding methodology: high risk
Loss to follow-up: partial/high risk
Participants 235 adults
Age not reported
50.2% male
70.6% European American
Drug use not reported
Alcohol use not reported
100% psychiatric history
Eligibility criteria: adults charged with a crime or misdemeanour who were booked into
county jail, had at least 1 prior booking and were diagnosed with a serious and pervasive
mental illness and were residents of the county involved. Pre-plea participants were
required to have no previous offences involving violence; post-adjudication participants
with prior violence were eligible if they were considered to no longer pose a threat
Interventions Court-based sentencing and case management intervention vs. treatment as usual
(I) MHTC and ACT case management (n = 137) vs. (C) treatment as usual (n = 98)
(I) received weekly or bi-weekly court supervision and frequent contact with case man-
agers, duration 18 months, followed by treatment as usual if required
(C) received traditional court proceedings and county mental health services as usual for
at least 18 months, which was less intensive than (I)
Outcomes Drug use (Addiction Severity Index, self report) during the last month at 12 months’
follow-up
Re-arrests dichotomous outcomes.
Notes This research was sponsored by a grant from the California State Board of Corrections,
the Mentally Ill Offender Crime Reduction Grant Program.
Contract/grant sponsor: California State Board of Corrections
No declaration of interest reported by the authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table
Allocation concealment (selection bias) Unclear risk Not reported
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Cosden 2003 (Continued)
Blinding of participants and personnel
(performance bias)
subjective outcomes
High risk The interviewer was not blind to the con-
dition of the
client
Blinding of participants and personnel
(performance bias)
objective outcomes
High risk The interviewer was not blind to the con-
dition of the
client
Blinding of outcome assessment (detection
bias)
subjective outcomes
Unclear risk No information available
Blinding of outcome assessment (detection
bias)
objective outcomes
Unclear risk No information available
Incomplete outcome data (attrition bias)
All outcomes
High risk 25% of the initial population could not be
located at the end of 12 months
Selective reporting (reporting bias) Unclear risk Not reported
Other bias High risk The relatively small number of clients in
each group resulted in chance variation on
some of the intake measures. Generalisabil-
ity issues and concerns about self report
measures and validity
Johnson 2012
Methods Allocation: random - wave randomisation
Randomisation method: independently generated randomisation sequence. Exact
methodology unclear
Similar on drug use: yes
Similar on criminal activity: yes
Blinding methodology: Principal investigator blinded to initial allocation, data collectors
blinded throughout study period.
Loss to follow-up: none reported
Participants 38 adults
Average age: 35 years (SD 9.2)
100% female
18% Hispanic, 18% African American
58% cocaine dependence, 24% opiate dependence, 21% marijuana dependence, 21%
sedative/hypnotic dependence
58% alcohol dependence
100% psychiatric history
Criteria used for mental health diagnoses: “MDD as determined by the Structured
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Clinical Interview for DSM-IV Axis I Disorders (SCID-I; First et al., 1996a) after at
least 4 weeks of abstinence and prison substance use treatment”
Description of mental health problem: major depressive disorder
Eligibility criteria: primary major depressive disorder as determined by the Structured
Clinical Interview for DSM-IV Axis I Disorders after at least 4 weeks of abstinence and
prison substance use treatment, minimum 17-item Hamilton Depression Scale score of
18, substance use disorder 1 month prior to incarceration as determined by the SCID,
10-24 weeks away from prison release. Women with bipolar disorder and psychotic
disorder were excluded
Interventions Prison-based, non-pharmacological intervention vs attention-matched control condition
(I) Interpersonal psychotherapy (n = 19) vs (C) psycho-education (n = 19)
Intervention group
Intervention participants receivedmanualised 60-75min group sessions 3 times per week
for 8 weeks plus pre-group, mid-group, and post-group individual sessions in prison
for the treatment of substance misuse and mental health problems. Participants in both
conditions also received 6 weekly post-release individual sessions to help maintain gains
and address crises as they transitioned to the community. Session lengths varied between
60 and 75 min because of time taken to assemble women within the facilities, occasional
early prison counts, and other facility logistics. In-prison treatment was condensed into
2months because many incarcerated women serve short sentences (30, 60, 90, 180 days)
. Group sessions were kept short (60 to 75 min) because prison providers advised us that
incarcerated women would have difficulty tolerating treatment sessions longer than this
length
Control group
Control condition participants received attention-matched manualised in-prison and
post-release psycho-education, which is described as co-occurring mental health and
substance use disorders (PSYCHOED). The psycho-education condition was adapted
from a class on co-occurring disorders for prisoners that had been used at the women’s
facilities in the past, but was not being used at the time of the study. It was designed to be
credible and engaging without focusing on the theorised active ingredients of interper-
sonal psychotherapy (e.g., focus on social support, relationships, life changes, analysis of
communication, and exploration of emotions). The stated purpose of PSYCHOEDwas
to help women become informed and empowered consumers of mental health treatment
services. The 24 in-prison sessions focused on the meaning of dual diagnosis, women’s
experience with dual diagnosis, major depression, bipolar disorder, each of the anxiety
disorders, post-traumatic stress disorder, personality disorders, psychotic disorders, eat-
ing disorders, and self care. Sessions for each disorder described symptoms (including
relevant self report tests), interactions between the disorder and substance use, effects of
the disorder on women in prison (including film clips and written stories), and disorder-
specific medication and psychosocial treatment options. When a woman in group had
symptoms of a disorder, the group discussed her treatment options and preferences. The
6 post-release sessions focused on women’s symptoms and connection with various men-
tal health and substance use treatment options in the community. Study treatments took
place in addition to prison treatment as usual. Treatment as usual consisted of prison
residential or day treatment for substance use disorder (typically 16 to 30 hours per week)
for all participants and prison mental health treatment as usual for most participants
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Outcomes Relapse within 3-month follow-up period, defined as using drugs on at least 10% of non-
incarcerated days or any positive breath test/urine drug screen. Hamilton Depression
Scale scores
Notes Work supported by US National Institute of Drug Abuse.
No declarations of interest were noted by the authors.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random sequence generated by person in-
dependent of rest of study. Wave randomi-
sation used with at least 8 weeks between
allocation to avoid contamination across
prison wings
Allocation concealment (selection bias) Low risk Allocation adequately concealed fromprin-
cipal investigator and research assistants.
An independent individual concealed the
assignment of each wave before the study
started. After the intake assessment was
complete, the principal investigator un-
sealed the waves treatment assignment
Blinding of participants and personnel
(performance bias)
subjective outcomes
Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
objective outcomes
Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
subjective outcomes
Low risk Adequate blinding throughout study. Re-
search assistants who conducted the follow-
up assessment at 3 months after prison re-
lease were kept blind to the condition
Blinding of outcome assessment (detection
bias)
objective outcomes
Low risk Adequate blinding throughout study. Re-
search assistants who conducted the follow-
up assessment at 3 months after prison re-
lease were kept blind to the condition
Incomplete outcome data (attrition bias)
All outcomes
Low risk
No loss to follow-up, intention-to-treat
analysis
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Selective reporting (reporting bias) High risk Did not report on SCID-I/SCID-II,
Trauma History Questionnaire, or Time-
line Followback
Other bias High risk Authors noted that the short timeline and
limited outcomes made it difficult to as-
sess relapse rates, as 26% of the sample re-
mained in residential treatment at the end
of the study
Lanza 2013
Methods Allocation: Allocation did not seem to be concealed
Randomisation method: randomisation table
Similar on drug use: No differences between the groups for “demographic characteristics”
but not sure if this includes drug use. unclear
Similar on criminal activity: No differences between the groups for “demographic char-
acteristics” but not sure if this includes criminal activity. unclear
Blinding methodology: Participants, investigators, and assessors were not blinded
Loss to follow-up: All participants lost to follow-up were reported in study flow diagram,
but the authors did not report if there were between-group differences
Participants 50 adults
Average age: overall mean 33.2 (SD 7.2) (range 21-49)
(cognitive behavioural therapy 35.2 (mean); acceptance and commitment therapy 31.1
(mean); control 33.1 (mean))
100% female
% white, not reported
% drug users: CBT 100%, ACT 83.3%, control 100%
% alcohol users: CBT 0%, ACT 16.7%, control 100%
% psychiatric history: 86% had at least 1 mental disorder
Eligibility criteria:
• met diagnostic criteria for current substance use disorder
• serving sentence of more than 6 months
Interventions Intervention1: cognitive behavioural therapy (CBT: n= 13) vs Intervention2: acceptance
and commitment therapy (ACT: n = 18) vs Control group (n = 13)
Intervention 1
16 weekly CBT group sessions lasting 90 minutes led by a trained therapist. CBT
was used to change behaviour through cognitive restructuring, where therapist works
with offender to identify thoughts that cause distress and uses CBT to alter resulting
behaviour. Treatment offenders were assessed by the therapist afterwards, and follow-
up was conducted at six months. The main outcome of the CBT intervention was to
increase abstinence from drug use; this was measured and corroborated by urine analysis
testing
Intervention 2
16 weekly ACT group sessions lasting 90 minutes led by a trained therapist. ACT seeks
to undermine the grip of the literal verbal content of cognition that provokes avoidance
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behaviour and constructs an alternative context in which behaviour aligned with one’s
values is more likely to occur. Sessions involve both experiential and didactic learning to
enable clients to experience and understand the key ACT processes. ACT helps offenders
to respond to previously avoided events in new ways and uses validation and empow-
erment. The ACT therapy was aimed at increasing substance use abstinence within the
prison population. Treatment offenders were assessed by the therapist afterwards, and
follow-up was conducted at six months
Control group
Control group received a mental health assessment and then after 6 months received
treatment. The offenders received a re-educational programme for inmates during the 6
months
Outcomes Abstinence: 3 months without drug use, self report, corroborated by urinalysis
Anxiety sensitivity measured by Anxiety Sensitivity Index
Mental disorders measured on Mini International Neuropsychiatric Interview
Notes Work supported by Trust for the Promotion of Scientific Applied Research and Tech-
nology in Asturias, Spain
A second publication reporting on the same trial comparing 2 arms of the 3-armed trial
can be found at: Lanza, P., Menedez, G.A. (2013). Acceptance and commitment therapy
for drug abuse in incarcerated women. Psicothema, 25,3,307-312
No conflict of interest reported by authors.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Use of random number table noted.
Allocation concealment (selection bias) Unclear risk No information reported.
Blinding of participants and personnel
(performance bias)
subjective outcomes
High risk Participants, investigators, and assessors
were not blinded to treatment allocation
Blinding of participants and personnel
(performance bias)
objective outcomes
High risk Participants and personnel were not
blinded to treatments.
Blinding of outcome assessment (detection
bias)
subjective outcomes
Low risk Urinalysis was used to corroborate self re-
ported abstinence
Blinding of outcome assessment (detection
bias)
objective outcomes
High risk Therapists assessed the participants in their
group.
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Similiar loss to follow-up across all 3
groups. A total of 9/50 lost (n = 4 for ACT,
n = 3 for CBT, n = 2 for control)
Selective reporting (reporting bias) Low risk All outcome measures were reported as ex-
pected
Other bias Low risk No other concerns.
Sacks 2004
Methods Allocation: random assignment
Randomisation method: unclear
Similar on drug use: no
Similar on criminal activity: yes
Blinding methodology: unknown/unclear risk
Loss to follow-up: adequate/low risk
Participants 236 adults
Mean age 34.3 years (SD 8.8)
100% male
49% white
100% drug-using
32% alcohol-using
100% psychiatric history
Eligibility criteria: prisoners who had both a serious mental disorder and a substance use
disorder
Interventions Secure establishment-based therapeutic community vs. treatment as usual
(I) Personal reflections TC and voluntary residential aftercare (n = 142) vs. (C) mental
health programme combined with a substance use education course (n = 94)
Intervention group
Therapeutic communities have long been recognized as a major drug abuse treatment
approach, particularly for the socially disaffiliated. TC has an established record of ef-
fectiveness in reducing drug use and criminality. The Personal Reflections initiative is a
modified TC residential treatment programme that uses a cognitive behavioral curricu-
lum within a foundation of TC principles to change attitudes and lifestyles in 3 critical
areas: substance abuse, mental illness, and criminal thinking and behavior. The inter-
vention group received a mixture of psycho-educational classes, cognitive behavioural
methods, medication, and group therapy. Activities were attended 5 days per week for 4-
5 hours per day with the rest of the day spent working in the prison; duration 12 months.
Aftercare included mental health counselling, medication and psychiatric services, and
basic skills. Activities were attended 3-7 days per week for 3-5 hours per day; duration
6 months
Control group
The control group received intensive psychiatric services with medication, weekly indi-
vidual therapy and counselling, and specialised groups of cognitive behavioural work,
anger management, therapy and education, domestic violence, parenting, and weekly
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Sacks 2004 (Continued)
drug/alcohol therapy with a 72-hour course on substance abuse education and relapse
prevention over a duration of 12 months
Outcomes Sacks 2004 - Primary study
Criminal activity regarding a new offence (official records) during the last 12 months at
12-months follow-up
Incarceration for a new offence (official records) during the last 12 months at 12-months
follow-up
Sullivan 2007 - Follow-up study
Drug use (self report) at 12 months
Notes Contract/grant sponsor:National Institute onDrugAbuse (NIDA); contract/grant num-
ber: P50 DA
7700.0003.
No declaration of interest reported by the authors.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants were randomly assigned p. 824
Allocation concealment (selection bias) Unclear risk Method of concealment not reported
Blinding of participants and personnel
(performance bias)
subjective outcomes
Unclear risk No information on blinding reported
Blinding of participants and personnel
(performance bias)
objective outcomes
Unclear risk No information on blinding reported
Blinding of outcome assessment (detection
bias)
subjective outcomes
Unclear risk No information on blinding reported
Blinding of outcome assessment (detection
bias)
objective outcomes
Unclear risk No information on blinding reported
Incomplete outcome data (attrition bias)
All outcomes
High risk Somedifference between the groups. At fol-
low-up, 82% for the (I) group and 69%
for the (C) group. ITT was performed and
missing data was added to the data set
Selective reporting (reporting bias) Unclear risk Limited information
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Other bias Unclear risk No other obvious concerns with the study
but difficult to assess
Sacks 2008
Methods Allocation: random assignment
Randomisation method: unclear
Similar on drug use: yes
Similar on criminal activity: yes
Blinding methodology: unknown
Loss to follow-up: high risk--intention to treat noted
Participants Sacks 2008 - primary study
573 adult women
Mean age 35.6 (SD 7.5)
100% female
47.8% white
99% drug-using
Eligibility criteria: female inmates with at least 6 months remaining until parole with se-
rious substance abuse problems requiring treatment and presenting a minimum/medium
security risk
Sacks 2012 - follow-up study at 6 and 12 months
468 adult females
Average age: 35.1 years (SD 7.9)
100% female
47% white
26% Hispanic
100% drug users (as measured by Standardized Offender Assessment score)
Alcohol use: not reported
58% lifetime mental health treatment
Eligibility criteria: female offenders at Denver Women’s Correctional Facility; at least 6
months, but no greater than 24 months remaining before parole eligibility; Colorado
Department of Corrections Standardized Offender Assessments score of 4 or higher
(indicating substance use disorder severe enough to require treatment); security risk level
allowing participation in programme; consented
Interventions (I) Therapeutic community programme (n = 257) vs (C) cognitive behavioural inter-
vention (n = 211)
Intervention group
Therapeutic communities were initially designed for use in community-based residen-
tial settings, and the model has been successfully adapted for inmate populations. The
model has been further modified for male inmates with co-occurring serious mental
and substance use disorders, with previous evidence showing positive outcomes for re-
incarceration, substance use, and mental health symptoms. The intervention involved a
6-month tenure in a separate residential building with programme activities 4 hours per
day, 5 days per week, supplemented by peer-led activities on weekends, and a further
4 hours per day, 5 days per week working within the prison complex. The programme
followed therapeutic community principles, with additional gender-specific aspects
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Control group
The control programme, known as the Intensive Outpatient Program, is the standard
treatment that the Colorado Department of Corrections offers to all female offenders
who have been classified as substance abusers. The intervention is designed to address
substance abuse and criminality, with a focus on prevention of relapse and recidivism.
The Intensive Outpatient Program substance abuse treatment curriculum consists of a
90-hour course, presented in an educational format (Strategies for Self-Improvement
and Change, Wanburg & Milkman, 1998), utilising a cognitive behavioural format to
address underlying issues of substance use/abuse and criminal behavior. The course is
completed within 15 weeks. Women in the programme can participate in multiple other
services facility-wide including mental health assessments
Outcomes Criminal activity, arrest, and drug-related activity (self reported) at 6 and 12 months,
and criminal record data (% incarcerated, mean days to incarceration) at 12 months
post-prison release
Self reported illegal drug use at 6 and 12 months
Notes Work supported by US Department of Health and Human Services, National Institutes
of Health, National Institute on Drug Abuse
No declarations of interest are noted by the authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No informationother than “were randomly
assigned”
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
subjective outcomes
Unclear risk No evidence to suggest blinding was done
but lack of information makes it difficult
to make an assessment
Blinding of participants and personnel
(performance bias)
objective outcomes
Unclear risk No evidence to suggest blinding was done
but lack of information makes it difficult
to make an assessment
Blinding of outcome assessment (detection
bias)
subjective outcomes
Unclear risk No evidence about whether the assessors
were blind
Blinding of outcome assessment (detection
bias)
objective outcomes
Unclear risk No evidence about whether the assessors
were blind
Incomplete outcome data (attrition bias)
All outcomes
High risk No loss to follow-up for re-incarceration
outcome but loss to follow-up for other
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outcomes unclear. ITT reported. Differ-
ences also noted between data collected us-
ing self report and official records. Inten-
tion-to-treat analysis used to analyse the
outcome measures
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk Protocol noted
Sacks 2011
Methods Allocation: random assignment
Randomisation method: random number list
Similar on drug use: yes
Similar on criminal activity: yes
Blinding methodology: open label - no blinding
Loss to follow-up: unclear risk
Participants 127 adults
Mean age 38.2 years (SD 9.9)
100% male
56% white
100% co-occurring substance use and mental illness
Alcohol use: unknown
61.8% with clinical level of psychological distress as measured by Global Severity Index
Eligibility criteria:male, diagnosedwith co-occurringmental and substance use disorders,
had participated in 1 of 2 prison substance abuse treatment programmes, were approved
for placement in a community corrections facility and were accepted by the provider
agency for placement in a community corrections facility
Interventions Secure establishment-based therapeutic community vs. parole supervision case manage-
ment
(I) re-entry modified TC (n = 71) vs. (C) parole supervision case management (n = 56)
Intervention group
The intervention consisted of a residential programme of 6 months’ duration. Formal
programme activities 3-7days perweek, 3-5hours each day. Participants hadprogressively
increasing independence, eventually being responsible for providing counsel, guidance,
and coaching for new members. Participants also worked in the community and saved
money for independent living. There were weekly group psycho-educational classes to
address the interrelationship between mental disorders and substance abuse, as well as
various other group and individual counselling sessions. Medication monitoring and
psychiatric services were on site. Participants were given assistance with housing and
encouragement for employment
Control group
The control participants were released to a community corrections facility, and left the
facility during the day to go to work, have treatment, and report to parole officers. The
control consisted of outreach and engagement activities, brokering community-based
46Interventions for drug-using offenders with co-occurring mental illness (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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services, and direct provision of support and counselling services. There was a weekly
relapse prevention group and daily medication monitoring. Psychiatric and substance
abuse services were provided by outside agencies (community parole officers helped client
choose). Unlike in the intervention, criminal thinking and behaviour were not specif-
ically addressed. The average participant attended 1 group per week and had monthly
psychiatric assessments
Outcomes Rate of re-incarceration, number of days until re-incarceration, involvement in self re-
ported criminal activity, number of days until self reported criminal activity. Alcohol
and drug offences (self reported) %. Other offences (self reported) %. All at 12 months
post-prison release
Notes This project received support from the Department of
Health and Human Services, National Institutes of Health,
NIDA (Grant 5R01DA019982-[01-05]).
No declarations of interest reported by the authors.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number list
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
subjective outcomes
Unclear risk “Open-label trial”, no blinding possible
Blinding of participants and personnel
(performance bias)
objective outcomes
Unclear risk “Open label trial”, no blinding possible
Blinding of outcome assessment (detection
bias)
subjective outcomes
Unclear risk No information about blinding presented
Blinding of outcome assessment (detection
bias)
objective outcomes
Unclear risk No information about blinding presented
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Some partial loss to follow-up
Selective reporting (reporting bias) Unclear risk Not reported
Other bias Low risk No other obvious concerns with the study
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Stein 2011
Methods Allocation: random assignment
Randomisation method: random numbers table
Similar on drug use: yes
Similar on criminal activity: unknown/unclear risk
Blinding methodology: unclear/unknown
Loss to follow-up: partial/unclear risk
Participants 189 adolescents
Mean age 17.12 years (SD 1.10). Range 14-19 years
85.7% male
32.8% white
88.9% marijuana use
63% alcohol use
68.5% had significant depressive symptomatology during past week at baseline (CES-
D)
Eligibility criteria: 14-19 years old, sentenced to juvenile correctional facility for 4-12
months, engaged in at least monthly marijuana use or binge-drinking in the year before
incarceration, used any alcohol or marijuana in the month prior to incarceration (or
prior to the offence leading to incarceration)
Interventions Secure establishment-based motivational interviewing vs. relaxation treatment
(I) MI (n = 96) vs. (C) relaxation training (n = 85)
Intervention group
The intervention was designed specifically to reduce substance use and its associated
risks and consequences. Consisted of 90-minute baseline intervention and 60-minute
booster intervention within 2 weeks of release
Comparison group
The comparison group consisted of 90-minute baseline intervention and 60-minute
booster intervention, and involved relaxation techniques as well as advice on risky be-
haviours associated with substance use
Outcomes Mean number of joints per day and mean percentage of days usedmarijuana at 3months
Notes Results presented for both high and low depressive symptom scores. Results used in this
review were for those identified as having high depressive symptomatology
This research was supported by National Institute on Drug Abuse Grant
R01 #13375 (to L.A.R. Stein, principal investigator).
No declaration of interest reported by the authors.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Random assignment using a random
number table”
Allocation concealment (selection bias) Unclear risk “Random number was placed in an enve-
lope and opened by research staff after the
baseline assessment”
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Stein 2011 (Continued)
Blinding of participants and personnel
(performance bias)
subjective outcomes
Unclear risk Researchers were blind until after the
baseline assessment. Participants were not
blinded
Blinding of participants and personnel
(performance bias)
objective outcomes
Unclear risk Researchers were blind until after the
baseline assessment. Participants were not
blinded
Blinding of outcome assessment (detection
bias)
subjective outcomes
Unclear risk Follow-up assessments at 3 months were
completed blind by the researchers but not
at any other time point
Blinding of outcome assessment (detection
bias)
objective outcomes
Unclear risk Follow-up assessments at 3 months were
completed blind by the researchers but not
at any other time point
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Some attrition, particularly for those indi-
viduals with more severe depression
Selective reporting (reporting bias) Unclear risk Limited information
Other bias High risk Short follow-up period and concerns about
self report measures
Wexler 1999
Methods Allocation: random assignment
Randomisation method: unclear/unknown
Similar on drug use: yes
Similar on criminal activity: yes
Blinding methodology: unknown/unclear risk
Loss to follow-up: adequate/low risk
Participants 715 adults
Mean age 30.9 years (SD 7.4)
100% male
37.8% white
100% drug-using
Alcohol use not reported
100% psychiatric history
Eligibility criteria: offenders with a drug problem who were 9-14 months from parole.
Offenders convicted of arson or sexual crimes to minors were not eligible
Interventions Secure establishment-based therapeutic community vs. no treatment
(I) Amity TC and (I1) voluntary residential aftercare (n = 247) vs. (C) waiting-list control
(n = 290)
(I) TC included a 2- to 3-month orientation phase, a 5- to 6-month treatment stage, and
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Wexler 1999 (Continued)
a 1- to 3-month re-entry phase; total duration 12 months. The intervention elements
included a needs assessment, education, group work, counselling, and prison industry
jobs
(I1) voluntary residential aftercare in the community for up to 12 months
(C) waiting-list control
Outcomes Wexler 1999a:
Incarceration (official records) during the last 12 months at 12 months’ follow-up
Incarceration (official records) during the last 24 months at 24 months’ follow-up
Wexler 1999b:
Incarceration (official records) during the last 36 months at 36 months’ follow-up
Prendergast 2003:
Arrest for any offence (self report), arrest for a drug offence (self report), incarceration
for any offence (official records) 12-months post-release
Prendergast 2004:
Incarceration (official records) during the last 60 months at 60 months’ follow-up
Drug use (self report) during the last 60 months at 60 months’ follow-up
Notes This study was a cooperative effort by the Center for Therapeutic Community Research
at
National Development and Research Institutes, Inc. and the California Department of
Corrections and Rehabilitation Office of Substance Abuse Programs. The evaluation was
funded by the National Institute of Drug Abuse, Grant #PAODA07700-01
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk It was noted that the participants were “ran-
domly” assigned and stratified by ethnic
makeup. Randomisation only applied to
the TC and not to aftercare
Allocation concealment (selection bias) Unclear risk No information provided
Blinding of participants and personnel
(performance bias)
subjective outcomes
Unclear risk No information on blinding was provided
Blinding of participants and personnel
(performance bias)
objective outcomes
Unclear risk No information on blinding was provided
Blinding of outcome assessment (detection
bias)
subjective outcomes
Unclear risk No information on blinding was provided
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Wexler 1999 (Continued)
Blinding of outcome assessment (detection
bias)
objective outcomes
Unclear risk No information on blinding was provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcomes for the first 12 months post-re-
lease were obtained for all 715 participants
Selective reporting (reporting bias) Unclear risk Information not reported
Other bias High risk Only the prison phase was randomised. Af-
tercare was voluntary and participants self
selected. Concerns about bias in self selec-
tion processes p.164-165
ACT: acceptance and commitment therapy; CBT: cognitive behavioural therapy; CES-D: Center for Epidemiologic Studies Depression
Scale; (C): control;DSM-IV:Diagnostic andStatisticalManual ofMentalDisorders, FourthEdition; (I): intervention; ITT: intention
to treat;MDD: major depressive disorder; MHTC: mental health treatment court; MI: motivational interviewing; SCID: Structured
Clinical Interview for DSM Disorders; SD: standard deviation; TC: therapeutic community.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Alemi 2010 Study population did not have co-occurring mental illness
Alessi 2011 Not original RCT. Data are from previous, older studies
Andersson 2014 Intervention not aimed at reducing drug use or criminal activity, or both
Anglin 1999 The study did not report relevant drug or crime outcome (or both) measures at both the pre- and
post-intervention periods
Awgu 2010 The study did not report relevant drug or crime outcome (or both) measures at both the pre- and
post-intervention periods
Azbel 2013 Intervention not aimed at reducing drug use or criminal activity, or both
Baldus 2011 Study protocol only
Baltieri 2014 Intervention not aimed at reducing drug use or criminal activity, or both
Barnes 2012 Intervention not aimed at reducing drug use or criminal activity, or both
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Bayanzadeh 2004 Did not provide mental health information
Berman 2004 Intervention not aimed at reducing drug use or criminal activity, or both
Black 2011 Not an offender population
Brady 2010 Not RCT
Braithwaite 2005 The study did not report relevant drug or crime outcome (or both) measures at both the pre- and
post-intervention periods
Breckenridge 2000 Evaluated a DWI Court for alcoholic offenders, not illicit drug use
Britt 1992 Did not provide mental health information
Brown 2001 3-arm study in which only 2 arms were randomised -- 1 treatment arm and control arm. Results
presented as both treatment arms combined vs. control
Brown 2013 Did not provide mental health information
Burdon 2013 Did not provide mental health information
Carr 2008 The population of the study was not 100% drug-using offenders that were specifically referred by
the criminal justice system to the intervention
Carroll 2006 Study population did not have co-occurring mental illness
Carroll 2011 Not offender population
Carroll 2012 Did not provide mental health information
Chandler 2006 The study did not report relevant drug or crime outcome (or both) measures at both the pre- and
post-intervention periods
Chaple 2014 No pre- and post-test measures of drug or crime, or both
Clair 2013 No pre- and post-test data on either drug or crime outcomes
Cogswell 2011 Did not present mental health information
Cornish 1997 Study population did not have co-occurring mental illness
Cosden 2003a Did not present mental health information
Cosden 2005 The study did not report relevant drug or crime outcome (or both) measures at both the pre- and
post-intervention periods
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Coviello 2010 Study population did not have co-occurring mental illness
Coviello 2012 Did not present mental health information
Cox 2013 Not an offender population
Cropsey 2011 Study population did not have co-occurring mental illness
Cropsey 2013 Did not present mental health information
Cullen 2011 Not an intervention aimed at reducing drug use or criminal activity, or both
Cusack 2010 Not an intervention aimed at reducing drug use or criminal activity, or both
D’Amico 2013 Did not present mental health information
Dakof 2010 Study population was mothers of offenders, not offenders themselves
Dana 2013 Not an RCT
DeFulio 2013 Not an RCT
Dembo 2000 The study did not report relevant drug or crime outcome (or both) measures at both the pre- and
post-intervention periods
The follow-up periods reported for the different groups were not equivalent
Deschenes 1994 Study population did not have co-occurring mental illness
Di Nitto 2002 The follow-up periods reported for the different groups were not equivalent
Diamond 2006 The study did not report relevant drug or crime outcome (or both) measures at both the pre- and
post-intervention periods
Dolan 2003 Study population did not have co-occurring mental illness
Dole 1969 No outcome based on mental health problems
Dugan 1998 The study did not report relevant drug or crime outcome (or both) measures at both the pre- and
post-intervention periods
Evans 2012 Not an RCT
Forsberg 2011 Study population did not have co-occurring mental illness
Freudenberg 2010 Study population did not have co-occurring mental illness
Friedman 2012 Not an RCT
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Frost 2013 Not an RCT
Gagnon 2010 Not offender population
Gil 2004 The study did not report relevant drug or crime outcome (or both) measures at both the pre- and
post-intervention periods
Gordon 2012 No pre- and post-test outcomes of drug or criminal activity, or both
Gordon 2013 No relevant primary data, all data presented considered a secondary post hoc analysis
Gottfredson 2002 Study population did not have co-occurring mental illness
Grohman 2004 The study did not report relevant drug or crime outcome (or both) measures at both the pre- and
post-intervention periods
Grommon 2013a Did not contain any mental health information
Grommon 2013b Did not contain any mental health information
Guydish 2011 Study population did not have co-occurring mental illness
Guydish 2014 Not criminal justice population
Haapanen 2002 Study population did not have co-occurring mental illness
Haasen 2010 Not offender population
Hanlon 1999 Study population did not have co-occurring mental illness
Harada 2012 No data at pre- and post-test on outcomes of drug or criminal activity, or both
Harrell 2001 The study did not report relevant drug or crime outcome (or both) measures at both the pre- and
post-intervention periods
Henderson 2010 The study did not report relevant drug or crime outcome (or both) measures at both the pre- and
post-intervention periods
Henggeler 1991 The study did not report relevant drug or crime outcome (or both) measures at both the pre- and
post-intervention periods
Henggeler 1999 Study population did not have co-occurring mental illness
Henggeler 2002 The study did not report relevant drug or crime outcome (or both) measures at both the pre- and
post-intervention periods
Henggeler 2006 Study population did not have co-occurring mental illness
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Henggeler 2012 Study population did not have co-occurring mental illness
Howells 2002 Study population did not have co-occurring mental illness
Hser 2011 Unclear if study looked at offender population
Hser 2013 Study population did not have co-occurring mental illness
Inciardi 2004 Some participants were not randomly selected into the treatment groups
Jain 2011 Not an offender population
Johnson 2011 Study population did not have co-occurring mental illness
Jones 2011 Evaluated a DWI Court for alcoholic offenders, not illicit drug use
Jones 2013 Study population did not have co-occurring mental illness
Katz 2007 The population of the study was not 100% drug-using offenders that were specifically referred by
the criminal justice system to the intervention
Kelly 2013 Study population did not have co-occurring mental illness
Kidorf 2013 Not an offender population
King 2014 Not an offender population
Kinlock 2005 Study population did not have co-occurring mental illness
Kinlock 2007 Study population did not have co-occurring mental illness
Kinlock 2008 Study population did not have co-occurring mental illness
Kinlock 2009 Conference proceedings only
Kinlock 2009b Study population did not have co-occurring mental illness
Kok 2013 Not offender population
Law 2012 The study did not report relevant drug or crime outcome (or both) measures at both the pre- and
post-intervention periods
Lee 2012 Study population did not have co-occurring mental illness
Liddle 2011 The study did not report relevant drug or crime outcome (or both) measures at both the pre- and
post-intervention periods
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Ling 2013 Not offender population
Lobmaier 2010 Study population did not have co-occurring mental illness
Lobmann 2007 Study population did not have co-occurring mental illness
Lobmann 2009 The study did not report relevant drug or crime outcome (or both) measures at both the pre- and
post-intervention periods
MacDonald 2007 Evaluated a DWI Court for alcoholic offenders, not illicit drug use
Magura 2009 Study population did not have co-occurring mental illness
Marlowe 2003 The study did not report relevant drug or crime outcome (or both) measures at both the pre- and
post-intervention periods
Marlowe 2005 Study population did not have co-occurring mental illness
Marlowe 2007 Participants were not randomised to treatment group but once in a group were randomised by level
of risk
Not an RCT
Marlowe 2008 Study population did not have co-occurring mental illness
Marsch 2014 Not offender population
Martin 1993 Study population did not have co-occurring mental illness
Mbilinyi 2011 Participants not recruited through criminal justice system
McKendrick 2007 The study did not report relevant drug or crime outcome (or both) measures at both the pre- and
post-intervention periods
McKenzie 2012 Did not present mental health information
Messina 2000 The population of the study was not 100% drug-using offenders that were specifically referred by
the criminal justice system to the intervention
The study did not report relevant drug or crime outcome (or both) measures at both the pre- and
post-intervention periods
Milloy 2011 The study did not report relevant drug or crime outcome (or both) measures at both the pre- and
post-intervention periods
Needels 2005 The population of the study was not 100% drug-using offenders that were specifically referred by
the criminal justice system to the intervention
56Interventions for drug-using offenders with co-occurring mental illness (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Nemes 1998 The population of the study was not 100% drug-using offenders that were specifically referred by
the criminal justice system to the intervention
The study did not report relevant drug or crime outcome (or both) measures at both the pre- and
post-intervention periods
Nemes 1999 The population of the study was not 100% drug-using offenders that were specifically referred by
the criminal justice system to the intervention
The study did not report relevant drug or crime outcome (or both) measures at both the pre- and
post-intervention periods
Nielsen 1996 Study population did not have co-occurring mental illness
Nosyk 2010 Not offender population
Petersilia 1992 Did not present mental health information
Petry 2005 Partial criminal justice population
Petry 2011 Not offender population
Polsky 2010 Not offender population
Prendergast 2008 Did not present mental health information
Prendergast 2009 The study did not report relevant drug or crime outcome (or both) measures at both the pre- and
post-intervention periods
Prendergast 2011 Study population did not have co-occurring mental illness
Proctor 2012 Study population did not have co-occurring mental illness
Reimer 2011 Not offender population
Robertson 2006 The population of the study was not 100% drug-using offenders that were specifically referred by
the criminal justice system to the intervention
Rosengard 2008 The study did not report relevant drug or crime outcome (or both) measures at both the pre- and
post-intervention periods
Rossman 1999 Study population did not have co-occurring mental illness
Rounsaville 2001 The study did not report relevant drug or crime outcome (or both) measures at both the pre- and
post-intervention periods
Rowan-Szal 2005 Not offender population
Rowan-Szal 2009 Not RCT
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Rowe 2007 The population of the study was not 100% drug-using offenders that were specifically referred by
the criminal justice system to the intervention
Sanchez-Hervas 2010 Not offender population
Schaeffer 2014 No mental health information
Schmiege 2009 No pre- and post-test data on drug or crime outcome measures, or both
Schwartz 2006 Not offender population
Shanahan 2004 Did not contain a population with mental illness
Sheard 2009 The study did not report relevant drug or crime outcome (or both) measures at both the pre- and
post-intervention periods
Siegal 1999 Not RCT
Sinha 2003 Did not contain a population with mental illness
Smith 2010 Study population did not have co-occurring mental illness
Solomon 1995 Not offender population
Specka 2013 Not offender population
Stanger 2009 The population of the study was not 100% drug-using offenders that were specifically referred by
the criminal justice system to the intervention
Staton-Tindall 2009 No control group, not an RCT
Stein 2006 No data pre- and post-test for drug or crime measures, or both
Stein 2010 Not offender population
Stevens 1998 The population of the study was not 100% drug-using offenders that were specifically referred by
the criminal justice system to the intervention
Svikis 2011 Not clear if offender population
Taxman 2006/Thanner 2003 Study population did not have co-occurring mental illness
Vagenas 2014 No pre- and post-test data on either drug or crime measures, or both
Vanderberg 2002 No pre- and post-test outcome data on crime or drug measures, or both
Walters 2014 No data on pre- or post-test outcome data on crime or drug measures, or both
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Wang 2010 Participants not in criminal justice system
Webster 2014 No data on pre- and/or post-test crime and/or drug measures
White 2006 Randomisation broken as 40% of control arm were allowed to receive treatment (acupuncture)
outside of the intervention
Williams 2011 Not RCT
Winstanley 2011 Not clear if offender population
Witkiewitz 2010 Not clear if offender population
Wolff 2012 No data at pre- and/or post-test measures of drug and/or crime measures
Wright 2011 No separate mental health data
Zlotnick 2009 Study population did not have co-occurring mental illness
RCT: randomised controlled trial
Characteristics of ongoing studies [ordered by study ID]
Springer ongoing
Trial name or title Naltrexone for opioid-dependent released HIV+ criminal justice populations
Referred to as NEWHOPE.
Methods Our specific aim is to conduct a placebo-controlled randomised controlled trial of depot NTX (d-NTX) for
HIV+ prisoners with opioid dependence who are transitioning to the community
150 participants within the criminal justice system in New Haven, Hartford, and Springfield. Subjects will
be randomised 2:1 to d-NTX or d-placebo for 6 months and observed for 12 months
Participants HIV-infected prisoners with opioid dependence who are treated with depot-NTX as they are transitioning
from the correctional to the community setting
150 participants
Interventions Depot-NTX versus placebo
Outcomes 6 and 12 months
HIV treatment (HIV-1 RNA levels, CD4 count, antiretroviral adherence, retention in care), substance abuse
(time to relapse to opioid use, % opioid negative urine results, opioid craving), adverse side effects and HIV
risk behavior (sexual and drug-related risks)
The public health relevance is that outcomes from this study will establish the efficacy, safety, and tolerability
of pharmacological therapy using NTX treatment among HIV+s and establish depot-NTX treatment as an
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Springer ongoing (Continued)
effective, evidence-based treatment for opioid dependence for released HIV+ prisoners
Starting date 2012
Contact information Yale University
Notes
NTX: naltrexone
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D A T A A N D A N A L Y S E S
Comparison 1. Therapeutic community
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Criminal activity 4 Risk Ratio (M-H, Random, 95% CI) Totals not selected
1.1 Re-arrests 2 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Re-incarceration 3 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. Mental health court
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Self report dichotomous criminal
activity
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 3. Motivational interviewing and cognitive skills
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Self report drug use continuous 1 Mean Difference (IV, Random, 95% CI) Totals not selected
2 Self report drug use dichotomous 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 4. Interpersonal psychotherapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Self report drug use dichotomous 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
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Analysis 1.1. Comparison 1 Therapeutic community, Outcome 1 Criminal activity.
Review: Interventions for drug-using offenders with co-occurring mental illness
Comparison: 1 Therapeutic community
Outcome: 1 Criminal activity
Study or subgroup Experimental Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Re-arrests
Sacks 2008 23/207 11/163 1.65 [ 0.83, 3.28 ]
Wexler 1999 144/251 106/177 0.96 [ 0.82, 1.13 ]
2 Re-incarceration
Sacks 2004 7/75 21/64 0.28 [ 0.13, 0.63 ]
Sacks 2008 27/207 29/163 0.73 [ 0.45, 1.19 ]
Sacks 2011 13/71 21/56 0.49 [ 0.27, 0.89 ]
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 2.1. Comparison 2 Mental health court, Outcome 1 Self report dichotomous criminal activity.
Review: Interventions for drug-using offenders with co-occurring mental illness
Comparison: 2 Mental health court
Outcome: 1 Self report dichotomous criminal activity
Study or subgroup Experimental Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Cosden 2003 104/137 71/98 1.05 [ 0.90, 1.22 ]
0.01 0.1 1 10 100
Favours MH court Favours control
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Analysis 3.1. Comparison 3 Motivational interviewing and cognitive skills, Outcome 1 Self report drug use
continuous.
Review: Interventions for drug-using offenders with co-occurring mental illness
Comparison: 3 Motivational interviewing and cognitive skills
Outcome: 1 Self report drug use continuous
Study or subgroup Experimental Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Stein 2011 86 33.8 (39.44) 76 41.22 (42.64) -7.42 [ -20.12, 5.28 ]
-100 -50 0 50 100
Favours experimental Favours control
Analysis 3.2. Comparison 3 Motivational interviewing and cognitive skills, Outcome 2 Self report drug use
dichotomous.
Review: Interventions for drug-using offenders with co-occurring mental illness
Comparison: 3 Motivational interviewing and cognitive skills
Outcome: 2 Self report drug use dichotomous
Study or subgroup Experimental Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Lanza 2013 10/30 4/11 0.92 [ 0.36, 2.33 ]
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 4.1. Comparison 4 Interpersonal psychotherapy, Outcome 1 Self report drug use dichotomous.
Review: Interventions for drug-using offenders with co-occurring mental illness
Comparison: 4 Interpersonal psychotherapy
Outcome: 1 Self report drug use dichotomous
Study or subgroup Experimental Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Johnson 2012 6/19 9/19 0.67 [ 0.30, 1.50 ]
0.01 0.1 1 10 100
Favours experimental Favours control
A D D I T I O N A L T A B L E S
Table 1. Mental health diagnoses
Study, year Criteria used for diagnoses Description of mental health problem
Cosden 2003 Determined by a psychiatrist/psychologist
on the basis of a clinical interview and ob-
servations
Mood disorder
Schizophrenia
Bipolar disorder
Other
Dual diagnosis
Johnson 2012 Hamilton Rating Scale for Depression
Median duration of index episode in
months
Number of depressive episodes
Number of previous suicide attempts
DSM-IV Axis I disorders using the SCID-
I/II.
Criteria for a major depressive disorder at
least 4 weeks after substance abuse treat-
ment
Minimum score of 18 on the Hamilton
Rating Scale for Depression
Lanza 2013 DSM-IV
Mini International Neuropsychiatric Inter-
view
Anxiety Sensitivity Index
Anxiety
Mental health disorders
Antisocial personality disorder
Major depressive disorder
Generalised anxiety disorder
Sacks 2004 DIS Diagnoses of lifetime Axis I or Axis II men-
tal disorder
Antisocial personality disorder
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Table 1. Mental health diagnoses (Continued)
Sacks 2008 Global Severity Index
Beck Depression Inventory
Lifetime of mental health
PTSD Symptom Scale - Interview Post-
traumatic Stress Diagnostic Scale
Depression
PTSD
Lifetime of mental health
Sacks 2011 DSM-IV diagnostic criteria
Beck Depression Inventory
Post Traumatic Stress Disorder Symptom
Scale
Brief Symptom Inventory
Global Severity Index
Depression
PTSD
Psychological distress
Stein 2011 CES-D Scale Scores > 16 indicate presence of significant
depression. 69.8% had
significant depressive symptoms
Wexler 1999;
Prendergast 2003; Prendergast 2004
Not specified Antisocial personality disorder
Phobias
PTSD
Depression
Dysthymia
Attention deficit hyperactivity disorder
CES-D: Center for Epidemiological Studies - Depression; DIS: Diagnostic Interview Schedule; DSM-IV: Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition; PTSD: post-traumatic stress disorder; SCID: Structured Clinical Interview for DSM
Disorders.
Table 2. Summary research evidence for the narrative synthesis
Paper, year Intervention Comparison Follow-up Outcome type Measurement Actual outcome
Cosden 2003 Sentencing
and case man-
agement (mental
health treatment
court and as-
sertive commu-
nity treat-
ment case man-
agement)
Treatment as
usual
6 and 12 months Criminal activity
dichotomous
Self report drug
use continuous
% and total
mean and SD
% arrested and
spent some time
in jail
% convicted of a
new crime
Mean Addic-
tion Severity In-
dex (drug) com-
posite score
Wexler 1999;
Prendergast
2003;
Prendergast
2004
Ther-
apeutic commu-
nity, counselling
and aftercare
Treatment as
usual and wait-
ing-list control
12, 24, 36
months
up to 5 years
Biological drug
use dichotomous
Criminal activity
continuous
Criminal activity
% and total
mean and SD
% testing posi-
tive
for illicit drugs at
12 months’ fol-
low-up
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Table 2. Summary research evidence for the narrative synthesis (Continued)
dichotomous
Self report drug
use dichotomous
Mean
months incarcer-
ated in the year
following release
% any arrest
% arrested for
drug crime
% arrested for
property crime
% arrested for vi-
olent crime
% arrested for
other crime
% used drugs
heavily in past
year at 5 years
Mean days until
re-incarceration
% re-
incarcerated
Mean days on
parole to first re-
turn to custody
% returned to
prison within 3
years post- parole
Sacks 2004 Modified thera-
peutic commu-
nity (Per-
sonal Reflections
therapeutic com-
munity and vol-
untary residen-
tial aftercare)
Intensive psychi-
atric services
12 months Criminal activity
continuous
Criminal activity
dichotomous
Self report drug
use dichotomous
Mean and SD
% and total
Mean number of
days until incar-
ceration
Mean number of
days until first
crime
% re-incarcera-
tion
%criminal activ-
ity
% alcohol/drug
offence
% other (non-
alcohol/drug) of-
fence
% illegal drug
use
Sacks 2011 Therapeutic
community (re-
entry modified)
Parole super-
vision case man-
agement
12 months Criminal activity
dichotomous
% with total % re-
incarcerated
% self reported
criminal activity
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Table 2. Summary research evidence for the narrative synthesis (Continued)
Sacks 2008 Therapeutic
community
Cogni-
tive behavioural
therapy
6 and 12 months Criminal activity
dichotomous
Criminal activity
self report and
official
Self report drug
use
% with total Criminal activ-
ity, arrest,
and drug- related
activity (self-re-
ported)
Criminal record
data (% incarcer-
ated, mean days
to incarceration)
% self-reported
illegal drug use
Johnson 2012 Interpersonal
psychotherapy
psycho-
educational
3 months biological drug
use
% with total Relapse within
3-month follow-
up period, de-
fined as using
drugs on at least
10% of non-in-
carcerated days
or any positive
breath test/urine
drug screen
Lanza 2013 Cogni-
tive behavioural
therapy and ac-
cep-
tance and com-
mitment therapy
control group 3 months Self report drug
use dichotomous
% and total Self report, cor-
roborated by uri-
nalysis
Stein 2011 (high
depression score)
Motivational in-
terviewing
Relaxation train-
ing
3 months Self report drug
use continuous
Mean and SD Mean joints per
day
Mean % days
used marijuana
SD: standard deviation
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A P P E N D I C E S
Appendix 1. Cochrane Central Register of Controlled Trials (CENTRAL) search strategy
CENTRAL search
1. prison*
2. offender*
3. (criminal* or probation or court*)
4. (secure next establishment*)
5. reoffend*
6. reincarcerat*
7. recidiv*
8. exoffend*
9. (jail or jails or incarcerat*)
10. (secure next facilit*)
11. (convict* or revocation or inmate* or (high next security))
12. PRISONERS
13. LAW ENFORCEMENT
14. JURISPRUDENCE
15. CRIME
16. #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15
17. SUBSTANCE-RELATED DISORDERS
18. ((substance or drug*) next (abuse* or misuse* or dependen*or use* or addict*))
19. (narcotics or chemical or opiate) next (dependen* or addict* or abuse* or misuse*))
20. ((heroin) next (addict* or dependen* or misuse* or abuse*))
21. ((crack) next (addict* or dependen* or misuse* or abuse* or use*))
22. ((cocaine next addict*) or (cocaine next dependenc*) or (cocaine next misuse*) or (cocaine next abuse*) or (cocaine next use*))
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(Continued)
23. ((amphetamine*) next (addict* or dependen* or misuse* or abuse* or use*))
24. (addicts or (dependence next disorder) or (drug next involved))
25. (street next drugs)
26. STREET DRUGS
27. DESIGNER DRUGS
28. NARCOTICS
29. COCAINE
30. AMPHETAMINES
31. ANALGESICS ADDICTIVE
32. ANALGESICS OPIOID
33. PSYCHOTROPIC DRUGS
34. opioid* or opiat*
35. #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34
35. (#16 and #35)
Appendix 2. MEDLINE search strategy
MEDLINE search
1. exp “Substance-Related-Disorders”/
2. ((drug or substance) adj (abuse* or addict* or dependen* or misuse*)).ti,ab
3. (drug* adj (treat* or intervention* or program*)
4. substance near (treat* or intervention* or program*)
5.(detox* or methadone) in ti,ab
6. narcotic* near (treat* or intervention* or program*)
7. 1 or 2 or 3 or 4 or 5 or 6
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(Continued)
8. prison*. ti,ab
9. exp “Prisoners”/
10. offender* or criminal* or inmate* or convict* or probation* or remand or felon*).ti,ab
11. exp “Prisons”/
12. 8 or 9 or 10 or 11
13. 7 and 12
Appendix 3. EMBASE search strategy
EMBASE search
1. (detox$ or methadone or antagonist prescri$).ti,ab.
2. detoxification/ or drug detoxification/ or drug withdrawal/ or drug dependence treatment/ or methadone/ ormethadone treatment/
or diamorphine/ or naltrexone/
3. (diamorphine or naltrexone or therapeutic communit$).ti,ab
4. morality/
5. (motivational interview$ or motivational enhancement).ti,ab
6. (counselling or counseling).ti,ab.
7. exp counseling/
8. (psychotherap$ or cognitive behavioral or cognitive behavioural).ti,ab
9. exp psychotherapy/
10. (moral adj3 training).ti,ab.
11. (cognitive restructuring or assertiveness training).ti,ab
12. reinforcement/ or self monitoring/ or self control/
13. (relaxation training or rational emotive or family relationship therap$).ti,ab
14. social learning/ or withdrawal syndrome/ or coping behavior/
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(Continued)
15. (community reinforcement or self monitoring or self control or self management or interpersonal skills).ti,ab
16. (goal$ adj3 setting).ti,ab.
17. (social skills adj3 training).ti,ab.
18. anger/ or lifestyle/
19. (basic skills adj3 training).ti,ab.
20. (relapse adj3 prevent$).ti,ab.
21. (craving adj3 (minimi$ or reduc$)).ti,ab.
22. (trigger or triggers or coping skills or anger management or group work).ti,ab
23. (lifestyle adj3 modifi$).ti,ab.
24. (high intensity training or resettlement or throughcare or aftercare or after care).ti,ab
25. aftercare/ or halfway house/
26. (brief solution or brief intervention$ or minnesota program$ or 12 step$ or twelve step$).ti,ab
27. (needle exchange or nes or syringe exchange or dual diagnosis or narcotics anonymous).ti,ab
28. self help/ or support group/
29. (self-help or selfhelp or self help or outreach or bail support or arrest referral$).ti,ab
30. exp urinalysis/ or rehabilitation/ or rehabilitation center/
31. (diversion or dtto or dttos or drug treatment or testing order$ or carat or carats).ti,ab
32. (combined orders or drug-free or drug free).ti,ab.
33. (peer support or evaluation$ or urinalysis or drug testing or drug test or drug tests).ti,ab
34. ((rehab or rehabilitation or residential or discrete) adj2 (service$ or program$)).ti,ab
35. (asro or addressing substance$ or pasro or prisons addressing or acupuncture or shock or boot camp or boot camps).ti,ab
36. (work ethic camp$ or drug education or tasc or treatment accountability).ti,ab
37. exp acupuncture/
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(Continued)
38. or/1-36
39. (remand or prison or prisoner or prisoners or offender$ or criminal$ or probation or court or courts).ti,ab
40. (secure establishment$ or secure facilit$).ti,ab.
41. (reoffend$ or reincarcerat$ or recidivi$ or ex-offender$ or jail or jails or goal or goals).ti,ab
42. (incarcerat$ or convict or convicts or convicted or felon or felons or conviction$ or revocation or inmate$ or high security).ti,ab
43. criminal justice/ or custody/ or detention/ or prison/ or prisoner/ or offender/ or probation/ or court/ or recidivism/ or crime/ or
criminal behavior/ or punishment/
44. or/39-43
45. 38 and 44
46. (substance abuse$ or substance misuse$ or substance use$).ti,ab
47. (drug dependanc$ or drug abuse$ or drug use$ or drug misuse$ or drug addict$).ti,ab
48. (narcotics adj3 (addict$ or use$ or misuse$ or abuse$)).ti,ab
49. (chemical dependanc$ or opiates or heroin or crack or cocaine or amphetamines or addiction or dependance disorder or drug
involved).ti,ab
50. substance abuse/ or drug abuse/ or analgesic agent abuse/ or drug abuse pattern/ or drug misuse/ or intravenous drug abuse/ or
multiple drug abuse/
51. addiction/ or drug dependence/ or narcotic dependence/ or exp narcotic agent/ or narcotic analgesic agent/
52. opiate addiction/ or heroin dependence/ or morphine addiction/
53. cocaine/ or amphetamine derivative/ or psychotropic agent/
54. or/46-53
55. 45 and 54
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Appendix 4. PsycINFO search strategy
PsycINFO
1. (detoxification in de) or (drug withdrawal in de)
2. (drug usage screening in de) or (methadone maintenance) in de
3. explode “Narcotic-Antagonists” in DE
4. 1 or 2 or 3
5. (counseling in de) or (explode “psychotherapeutic-counseling” in de)
6. (explode “cognitive-therapy” in de) or (explode “psychotherapeutic-techniques” in de)
7. (cognitive restructuring in de) or (assertiveness training in de)
8. explode “relaxation-therapy” in de
9. (rational emotive therapy in de) or (rational-emotive therapy in de)
10. (explode “self monitoring” in de) or (explode self-monitoring) in de
11. (goal setting in de) or (self control in de) or (explode “self-management” in de)
12. (social skills in de) or (relapse prevention in de) or (craving in de) or (coping behavior in de)
13. (anger control in de) or (explode “group-psychotherapy” in de) or (brief psychotherapy in de)
14. (explode “behavior-modification” in de) or (posttreatment followup in de) or (aftercare in de)
15. (halfway houses in de) or (twelve step programs in de)
16. (dual diagnoses in de) or (explode “self help techniques” in de) or (outreach programs in de) or (court referrals in de)
17. (peer pressure in de) or (urinalysis in de)
18. (drug rehabilitation in de) or (residential care institutions in de) or (acupuncture in de) or (drug education in de)
19. (detox* or methadone or antagonist prescri* or diamorphine or naltrexone or therapeutic communit*) in ti,ab
20. (motivational interview* or motivational enhancemen* or counseling or psychotherapy or psychotherapies) in ti,ab
21. (cognitive behav* or cognitive therapy or cognitive therapies or moral training or cognitive restructuring) in ti,ab
22. (assertiveness training or relaxation training or relaxation therapy or relaxation therapies) in ti,ab
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(Continued)
23. (rational emotive therap* or rational emotive behav* therap* or family relationship therap* or community reinforcement) in ti,ab
24. (self-monitor* or self monitor* or goal setting or self control or self-control or self management or self-management) in ti,ab
25. (interpersonal skills training or social skills training or basic skills training) in ti,ab
26. (relapse with prevent*) in ti,ab
27. (craving near reduc*) in ti,ab
28. craving with (reduc* in ti,ab)
29. (trigger* or coping skills or anger management or group work or lifestyle modif* or high intensity training or resettlement) in ti,
ab
30. (throughcare or aftercare or after care or brief solution* or brief intervention*) in ti,ab
31. (minnesota or 12 step* or twelve step* or needle exchange or nes or syringe exchange or dual diagnosis) in ti,ab
32. (narcotics anonymous or self-help or self help or outreach or bail support or arrest referral*) in ti,ab
33. (diversion or dtto* or testing order* or carat* or counseling assessment referral or combined order or combined orders or drug
free wing* or drug free environment*) in ti,ab
34. (peer support or user evaluations or urinalysis or urinalyses or mandatory drug test* or rehabilitation or discrete service* or discrete
program*) in ti,ab
35. (residential program* or residential scheme* or asro or addressing substance* or pasro or prisons addressing substance) in ti,ab
36. (acupuncture or shock or boot camp* or work ethic or drug education or tasc or treatment accountability) in ti,ab
37. or/4-36
38. (secure facilities or convict* or revocation or inmate* or high security) in ti,ab
39. (prisoners in de) or (explode “correctional-institutions” in de)
40. (perpetrators in de) or (explode criminals in de)
41. (probation in de) or (parole in de) or (incarceration in de) or (recidivism in de) or (criminal conviction in de) or (crime in de)
42. (remand or prison* or offender* or criminal* or probation or court or courts or secure establishment* or reoffend* or reincarcerat*
or recidivi* or ex-offender* or jail or jails or incarcerat*) in ti,ab
43. (drug abuse in de) or (explode “inhalant-abuse” in de) or (explode “drug-dependency” in de)
44. (polydrug abuse in de) or (drug abuse in de) or (intravenous drug usage in de)
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(Continued)
45. (narcotic drugs in de) or (heroin in de) or (cocaine in de) or (explode amphetamine in de)
46. (substance abuse* or substance misuse* or substance user*) in ti,ab
47. (drug dependen* or drug abuse* or drug misuse* or drug addict* or drug use) in ti,ab
48. (narcotic abuse* or narcotic misuse* or chemical dependen* or opiate misuse* or opiate abuse*) in ti,ab
49. (heroin use* or heroin addict* or heroin misuse* or heroin abuse*) in ti,ab
50. (crack use* or crack addict* or crack misuse* or crack abuse*) in ti,ab
51. (cocaine use* or cocaine addict* or cocaine misuse* or cocaine abuse*) in ti,ab
52. (amphetamine* use* or amphetamine* addict* or amphetamine* misuse* or amphetamine* abuse*) in ti,ab
53. (dependence disorder or drug involved or dug-involved) in ti,ab
54. #38 or #39 or #40 or #41 or #42
55. #4 or #43 or #44 or #45 or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53
56. #37 and #54 and #55
Appendix 5. PASCAL, SciSearch, Social SciSearch, Wilson Applied Science and Technology
Abstracts search strategy
PASCAL search
1. (DETOX? OR METHADONE OR ANTAGONIST()PRESCRI?)/TI,AB
2. METHADONE/DE OR NALTREXONE/DE
3. (DIAMORPHINE OR NALTREXONE)/TI,AB
4. THERAPEUTIC()COMMUNITY/DE OR THERAPEUTIC()COMMUNIT?)/TI,AB
5. (MOTIVATIONAL()INTERVIEW? ORMOTIVATIONAL()ENHANCEMENT)/TI,AB
6. (COUNSELLING OR COUNSELING)/TI,AB
7. COUNSELING/DE
8. (PSYCHOTHERAP? OR COGNITIVE()BEHAVIORAL OR COGNITIVE()BEHAVIOURAL)/TI,AB
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(Continued)
9. PSYCHOTHERAPY!/DE
10. (MORAL(3W)TRAINING)/TI,AB
11. (COGNITIVE()RESTRUCTURING OR ASSERTIVENESS()TRAINING)/TI,AB
12. ASSERTIVENESS/DE OR RELAXATION()TECHNIQUES/DE
13. (RELAXATION()TRAINING OR RATIONAL()EMOTIVE OR FAMILY()RELATIONSHIP()THERAP?)/TI,AB
14. FAMILY()RELATIONS/DE
15. (COMMUNITY()REINFORCEMENT OR SELF()MONITORING OR SELF()CONTROL OR SELF()MANAGEMENT
OR INTERPERSONAL()SKILLS)/TI,AB
16. (GOAL?(3W)SETTING)/TI,AB
17. (SOCIAL(3W)TRAINING)/TI,AB
18. SOCIAL RESPONSIBILITY/DE
19. (BASIC()SKILLS(3W)TRAINING)/TI,AB
20. (RELAPSE(3W)PREVENT?)/TI,AB
21. (CRAVING(3W)(MINIMI? OR REDUC?))/TI,AB
22. (TRIGGER OR TRIGGERS OR COPING()SKILLS OR ANGER()MANAGEMENT OR GROUP()WORK)/TI,AB
23. (LIFESTYLE(3W)MODIFI?)/TI,AB
24. (HIGH()INTENSITY()TRAININGORRESETTLEMENTORTHROUGHCARE ORAFTERCAREORAFTER()CARE)
/TI,AB
25. ADAPTATION,-PSYCHOLOGICAL!/DE OR ANGER/DE OR LIFE()STYLE/DE OR AFTER()CARE/DE ORHALFWAY
()HOUSES/DE
26. (BRIEF()SOLUTION OR BRIEF()INTERVENTION? OR MINNESOTA()PROGRAM? OR 12()STEP? OR TWELVE()
STEP?)/TI,AB
27. (NEEDLE()EXCHANGE OR NES OR SYRINGE()EXCHANGE OR DUAL()DIAGNOSIS OR NARCOTICS()ANONY-
MOUS)/TI,AB
28. NEEDLE-EXCHANGE()PROGRAMS/DE
29. (SELF-HELP OR SELFHELP OR SELF()HELP OR OUTREACH OR BAIL()SUPPORT OR ARREST()REFERRAL?)/TI,
AB
30. SELF-HELP()GROUPS/DE OR URINALYSIS/DE OR SUBSTANCE()ABUSE()DETECTION/DE
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(Continued)
31. (DIVERSION ORDTTO ORDTTOS ORDRUG()TREATMENT OR TESTING()ORDER? ? OR CARAT OR CARATS)
/TI,AB
32. (COMBINED()ORDERS OR DRUG-FREE OR DRUG()FREE)/TI,AB
33. (PEER()SUPPORT OR EVALUATION? ? OR URINALYSIS OR DRUG()TESTING OR DRUG()TEST? ?)/TI,AB
34. ((REHAB OR REHABILITATION OR RESIDENTIAL OR DISCRETE)(2W)(SERVICE? ? OR PROGRAM?))/TI,AB
35. (ASROORADDRESSING()SUBSTANCE?ORPASROORPRISONS()ADDRESSINGORACUPUNCTUREORSHOCK
OR BOOT()CAMP OR BOOT()CAMPS)/TI,AB
36. (WORK()ETHIC()CAMP? ? OR DRUG()EDUCATION OR TASC OR TREATMENT()ACCOUNTABILITY)/TI,AB
37. ACUPUNCTURE-THERAPY!/DE OR ACUPUNCTURE/DE OR HEALTH()EDUCATION/DE OR SUBSTANCE()
ABUSE()TREATMENT()CENTERS/DE
38. S1:S3
39. S4:S37
40. S38 AND S39
40. (REMAND OR PRISON OR PRISONER OR PRISONERS OR OFFENDER? ? OR CRIMINAL? ? OR PROBATION OR
COURT OR COURTS)/TI,AB
41. (SECURE()ESTABLISHMENT? ? OR SECURE()FACILIT?)/TI,AB
42. (REOFFEND? OR REINCARCERAT? OR RECIDIVI? OR EX()OFFENDER? ? OR JAIL OR JAILS)/TI,AB
43. (INCARCERAT? OR CONVICT OR CONVICTS OR CONVICTED OR FELON? ? OR CONVICTION? ? OR REVO-
CATION OR INMATE? ? OR HIGH()SECURITY)/TI,AB
44. PRISONERS/DE OR LAW()ENFORCEMENT/DE OR JURISPRUDENCE/DE
45. S40:S44
46. S40 AND S45
47. (SUBSTANCE()ABUSE? OR SUBSTANCE()MISUSE? OR SUBSTANCE()USE?)/TI,AB
48. (DRUG()DEPENDANC? OR DRUG()ABUSE? OR DRUG()USE? OR DRUG()MISUSE? OR DRUG()ADDICT?)/TI,AB
49. (NARCOTICS(3W)(ADDICT? OR USE? OR MISUSE? OR ABUSE?))/TI,AB
50. (CHEMICAL()DEPENDANC? OR OPIATES OR HEROIN OR CRACK OR COCAINE OR AMPHETAMINES OR
ADDICTION OR DEPENDENCE()DISORDER OR DRUG()INVOLVED)/TI,AB
77Interventions for drug-using offenders with co-occurring mental illness (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
51. SUBSTANCE-RELATED()DISORDERS/DE OR AMPHETAMINE-RELATED()DISORDERS/DE OR COCAINE-RE-
LATED()DISORDERS/DE OR MARIJUANA ()ABUSE/DE
52. OPIOID-RELATED-DISORDERS!/DE OR PHENCYCLIDINE()ABUSE/DE OR SUBSTANCE()ABUSE()INTRA-
VENOUS/DE
53. STREET()DRUGS/DE OR DESIGNER()DRUGS/DE OR NARCOTICS/DE
54. COCAINE!/DE OR AMPHETAMINES!/DE OR ANALGESICS()OPIOID/DE
55. S47:S54
56. S46 AND S55
57. (DETOXIFICATION OR METHADONE OR ANTAGONIST-PRESCRIBING)/DE FROM 144,34,434,7,99,65,35,6
58. (DIAMORPHINE OR NALTREXONE)/DE FROM 144,34,434,7,99,65,35,6
59. THERAPEUTIC-COMMUNITY)/DE FROM 144,34,434,7,99,65,35,6
60. (MOTIVATIONAL-INTERVIEW OR MOTIVATIONAL-ENHANCEMENT)/DE FROM 144,34,434,7,99,65,35,6
61. (COUNSELLING OR COUNSELING)/DE FROM 144,34,434,7,99,65,35,6
62. (PSYCHOTHERAPY! OR COGNITIVE-BEHAVIORAL OR COGNITIVE-BEHAVIOURAL)/DE FROM 144,34,434,7,
99,65,35,6
63. (MORAL-TRAINING)/DE FROM 144,34,434,7,99,65,35,6
64. (COGNITIVE-RESTRUCTURING OR ASSERTIVENESS-TRAINING)/DE FROM 144,34,434,7,99,65,35,6
65. (RELAXATION-TRAINING OR RATIONAL-EMOTIVE OR FAMILY-RELATIONSHIP-THERAPY)/DE FROM 144,34,
434,7,99,65,35,6
66. FAMILY-RELATIONS/DE
67. (COMMUNITY-REINFORCEMENT OR SELF-MONITORING OR SELF-CONTROL OR SELF-MANAGEMENTOR
INTERPERSONAL-SKILLS)/DE FROM 44,34,434,7,99,65,35,6
68. (GOAL-SETTING)/DE FROM 144,34,434,7,99,65,35,6
69. (SOCIAL-SKILLS-TRAINING)/DE FROM 144,34,434,7,99,65,35,6
70. SOCIAL-RESPONSIBILITY/DE
71. (BASIC-SKILLS-TRAINING)/DE FROM 144,34,434,7,99,65,35,6
72. (RELAPSE-PREVENTION)/DE FROM 144,34,434,7,99,65,35,6
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73. CRAVING/DE FROM 144,34,434,7,99,65,35,6
74. (TRIGGER OR COPING-SKILLS OR ANGER-MANAGEMENT OR GROUP-WORK)/DE FROM 144,34,434,7,99,65,
35,6
75. (LIFESTYLE-MODIFICATION)/DE FROM 144,34,434,7,99,65,35,6
76. (HIGH-INTENSITY-TRAINING OR RESETTLEMENT OR THROUGHCARE OR AFTERCARE OR AFTER-CARE)/
DE FROM 144,34,434,7,99,65,35,6
77. (BRIEF-SOLUTION OR BRIEF-INTERVENTIONS OR MINNESOTA-PROGRAM OR 12-STEP-PROGRAM OR
TWELVE-STEP-PROGRAM)/DE FROM 144,34,434,7,99,65,35,6
77. (NEEDLE-EXCHANGE OR SYRINGE-EXCHANGE OR DUAL-DIAGNOSIS OR NARCOTICS-ANONYMOUS)/DE
FROM 144,34,434,7,99,65,35,6
79. (SELF-HELP OR OUTREACH OR BAIL-SUPPORT OR ARREST-REFERRAL)/DE FROM 144,34,434,7,99,65,35,6
80. (DRUG-TREATMENT OR TESTING-ORDERS OR CARAT)/DE FROM 144,34,434,7,99,65,35,6
81. (COMBINED-ORDERS OR DRUG-FREE)/DE FROM 144,34,434,7,99,65,35,6
82. (PEER-SUPPORT OR EVALUATION OR URINALYSIS OR DRUG-TESTING OR DRUG-TESTS)/DE FROM 144,34,
434,7,99,65,35,6
83. (REHABILITATION OR RESIDENTIAL OR DISCRETE-SERVICES)/DE FROM 144,34,434,7,99,65,35,6
84. (ASRO OR PASRO ACUPUNCTURE OR BOOT-CAMP)/DE FROM 144,34,434,7,99,65,35,6
85. (WORK-ETHIC-CAMP OR DRUG-EDUCATION OR TASC OR TREATMENT-ACCOUNTABILITY)/DE FROM 144,
34,434,7,99,65,35,6
86. (REMAND OR PRISON OR PRISONER OR PRISONERS OR OFFENDER OR OFFENDERS OR CRIMINAL OR
CRIMINALS OR PROBATION OR COURT OR COURTS)/DE FROM 144,34,434,7,99,65,35,6
87. (SECURE-ESTABLISHMENTS OR SECURE-FACILITY)/DE FROM 144,34,434,7,99,65,35,6
88. (REOFFENDERS OR REINCARCERATION OR RECIDIVISM OR EX-OFFENDERS OR JAILS)/DE FROM 144,34,
434,7,99,65,35,6
89. (INCARCERATIONORCONVICTORCONVICTSORFELONORFELONSORCONVICTIONSORREVOCATION
OR INMATE OR INMATES OR HIGH-SECURITY)/DE FROM 144,34,434,7,99,65,35,6
90. (SUBSTANCE-ABUSE OR SUBSTANCE-MISUSE OR SUBSTANCE-USE)/DE FROM 144,34,434,7,99,65,35,6
91. (DRUG-DEPENDANCEORDRUG-DEPENDENCYORDRUG-ABUSEORDRUG-MISUSEORDRUG-ADDICT OR
DRUG-ADDICTION)/DE FROM 144,34,434,7,99,65,35,6
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92. (CHEMICAL-DEPENDANCY OR OPIATE-DEPENDENCY OR HEROIN-DEPENDENCY OR CRACK-DEPEN-
DENCY OR COCAINE-DEPENDENCY OR AMPHETAMINES OR ADDICTION OR DEPENDENCE-DISORDER OR
DRUG-INVOLVED)/DE FROM 144,34,434,7,99,65,35,6
93. S40 OR S57:S85
94. S45 OR S86:S89
95. S55 OR S90:S92
96. S93 AND S94 AND S95
Appendix 6. ASSIA search strategy
ASSIA search
1. remand
2. prison or prisoner or prisoners
3. offender*
4. criminal*
5. probation
6. court or courts
7. tribunal or tribunals
8. secure establishment*
9. secure facilit*
10. reoffend*
11. reincarcerat*
12. recidivi*
13. ex-offender*
14. jail or jails
15. incarcerat*
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(Continued)
16. convict or convicts
17. convicted
18. felon or felons
19. conviction*
20. reconviction*
21. high security
22. law enforcement
23. Substance abuse* or substance misuse* or substance use*
24. drug dependanc* or drug abuse* or drug use*
25. drug misuse* or drug addict*
26. narcotics addict* narcotics use* narcotics misuse* narcotics abuse*
27. chemical dependanc*
28. opiates
29. heroin
30. crack
31. cocaine
32. amphetamines
33. cocaine
34. addiction
35. dependence disorder*
36. drug involved
37. Substance-related disorders
38. amphetamine-related disorders
39. cocaine-related disorders
40. marijuana abuse
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41. opioid-related disorders
42. street drugs
43. designer drugs
44. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22
45. 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43
46. 44 and 45
Appendix 7. Sociological Abstracts search strategy
Sociological Abstracts
1. remand in de
2. detention in de
3. prisoners in de
4. prisons in de
5. offenders in de
6. parole in de
7. probation in de
8. correctional system in de
9. courts in de
10. imprisonment in de
11. criminal justice in de
12. criminal proceedings in de
13. recidivism in de
14. jail in de
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15. institutionalization (persons) in de
16. conviction/convictions in de
17. (remand or prison* or offender* or criminal* or probation or court or courts or secure establishment*) in ti,ab
18. (reoffend* or reincarcerat* or recidivi* or ex-offend* or jail or jails or incarcerat* or secure facilit* or convict* or revocation or
inmate*) in ti,ab
19. #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19
20. substance abuse in de
21. explode “Drug-Abuse” in DE
22. “Drug-Injection” in DE
23. explode “Narcotic-Drugs” in DE
24. “Cocaine-” in DE
25. “Addiction-” in DE
26. explode “Psychedelic-Drugs” in DE
27. (substance abuse* or substance misuse* or substance use*) in ti,ab
28. (drug abuse* or drug misuse* or drug use*) in ti,ab
29. (drug dependenc* or drug addict* or narcotics abuse* or narcotics use* or narcotics misuse* or narcotics addict*) in ti,ab
30. (chemical dependenc* or opiate abuse* or opiate misuse* or opiate use* or opiate addict*) in ti,ab
31. (heroin abuse* or heroin misuse* or heroin use* or heroin addict*) in ti,ab
32. (crack abuse* or crack misuse* or crack use* or crack addict*) in ti,ab
33. (cocaine abuse* or cocaine misuse* or cocaine use* or cocaine addict*) in ti,ab
34. (amphetamine* abuse* or amphetamine* misuse* or amphetamine* use* or amphetamine* addict*) in ti,ab
35. (dependence disorder or drug involved) in ti,ab
36. #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35
37. #19 and #36
38. “Detoxification-” in DE
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39. “Methadone-Maintenance” in DE
40. “Counseling-” in DE
41. “Psychotherapy-” in DE
42. “Assertiveness-” in DE
43. (detoxification in de) or (methadone maintenance in de) or (treatment programs in de)
44. (counseling in de) or (psychotherapy in de) or (assertiveness in de) or (group therapy in de) or (goals in de) or (self control in de)
45. (interpersonal communication in de) or (social interaction in de) or (social competence in de) or (coping in de)
46. (social behavior in de) or (group work in de) or (lifestyle in de)
47. (after care in de) or (support networks in de) or (self help in de) or (self help groups in de) or (outreach programmes in de)
48. (outreach programs in de) or (referral in de) or (delinquency prevention in de) or (diversion/diversions in de)
49. (peer groups in de) or (peer influence in de) or (drug use screening in de) or (rehabilitation in de) or (work experience in de)
50. (detox* or methadone maintenance or methadone prescri* or antagonist prescri* or dimorphine or naltrexone) in ti,ab
51. (therapeutic communit* or motivational interview* or motivational enhance* or counseling or counselling or psychotherapy or
cognitive behavi*) in ti,ab
52. (moral training or cognitive restructuring or assertiveness training or relaxation training) in ti,ab
53. (rational-emotive or rational emotive or family relationship therap* or community reinforcement or self monitoring or goal setting
or self control training) in ti,ab
54. (self management or interpersonal skills or social skills or basic skills or relapse prevent* or prevent* relapse or craving reduc* or
reduc* craving) in ti,ab
55. (trigger* or coping skills or anger management or group work or lifestyle modif* or high intensity training or resettlement or
throughcare) in ti,ab
56. (aftercare or after care or brief solution or brief intervention* or 12 step* or twelve step* or minnesota program* or needle exchange
or nes) in ti,ab
57. (syringe exchange or dual diagnosis or narcotics anonymous or self help or selfhelp or outreach or bail support) in ti,ab
58. (arrest referral* or diversion or dtto or dttos or drug treatment or carat or carats or counseling assessment or combined orders) in
ti,ab
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59. (drug-free or drug free or peer support or evaluation* or urinalysis or drug testing or drug use screen* or rehabilitation or discrete
service* or discrete program*) in ti,ab
60. (residential program* or residential scheme* or residential service*) in ti,ab
61. (asro or addressing substance or pasro or prisons addressing or acupuncture or shock or boot camp*) in ti,ab
62. (work ethic or drug education or tasc or treatment accountability) in ti,ab
63. #38 or #39 #or #40 or #41 or #42 or #43 or #44 or #45 or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #
55 or #56 or #57 or #58 or #59 or #60 or #61 or #62
64. #37 and #63
Appendix 8. HMIC search strategy
HMIC
1. remand in de
2. detention in de
3. prisoners in de
4. prisons in de
5. offenders in de
6. parole in de
7. probation in de
8. correctional system in de
9. courts in de
10. imprisonment in de
11. criminal justice in de
12. criminal proceedings in de
13. recidivism in de
14. jail in de
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15. institutionalization (persons) in de
16. conviction/convictions in de
17. (remand or prison* or offender* or criminal* or probation or court or courts or secure establishment*) in ti,ab
18. (reoffend* or reincarcerat* or recidivi* or ex-offend* or jail or jails or incarcerat* or secure facilit* or convict* or revocation or
inmate*) in ti,ab
19. #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18
20. substance abuse in de
21. explode “Drug-Abuse” in DE
22. “Drug-Injection” in DE
23. explode “Narcotic-Drugs” in DE
24. “Cocaine-” in DE
25. “Addiction-” in DE
26. explode “Psychedelic-Drugs” in DE
27. (substance abuse* or substance misuse* or substance use*) in ti,ab
28. (drug abuse* or drug misuse* or drug use*) in ti,ab
29. (drug dependenc* or drug addict* or narcotics abuse* or narcotics use* or narcotics misuse* or narcotics addict*) in ti,ab
30. (chemical dependenc* or opiate abuse* or opiate misuse* or opiate use* or opiate addict*) in ti,ab
31. (heroin abuse* or heroin misuse* or heroin use* or heroin addict*) in ti,ab
32. (crack abuse* or crack misuse* or crack use* or crack addict*) in ti,ab
33. (cocaine abuse* or cocaine misuse* or cocaine use* or cocaine addict*) in ti,ab
34. (amphetamine* abuse* or amphetamine* misuse* or amphetamine* use* or amphetamine* addict*) in ti,ab
35. (dependence disorder or drug involved) in ti,ab
36. #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35
37. #19 and #36
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PAIS
1. ((reoffend* or reincarcerat* or recidivi* or ex-offend* or jail or jails or incarcerat* or secure facilit* or convict* or revocation or
inmate*) in ti,ab)
2. ((remand or prison* or offender* or criminal* or probation or court or courts or secure establishment*) in ti,ab)
3. ((drug dependenc* or drug addict* or narcotics abuse* or narcotics use* or narcotics misuse* or narcotics addict*) in ti,ab)
4. ((drug abuse* or drug misuse* or drug use*) in ti,ab) or ((substance abuse* or substance misuse* or substance use*) in ti,ab)
5. ((detox* or methadone maintenance or methadone prescri* or antagonist prescri* or dimorphine or naltrexone) in ti,ab)
6. ((dependence disorder or drug involved) in ti,ab)
7. ((amphetamine* abuse* or amphetamine* misuse* or amphetamine* use* or amphetamine* addict*) in ti,ab)
8. ((cocaine abuse* or cocaine misuse* or cocaine use* or cocaine addict*) in ti,ab)
9. ((crack abuse* or crack misuse* or crack use* or crack addict*) in ti,ab)
10. ((heroin abuse* or heroin misuse* or heroin use* or heroin addict*) in ti,ab)
11. ((chemical dependenc* or opiate abuse* or opiate misuse* or opiate use* or opiate addict*) in ti,ab)
12. ((moral training or cognitive restructuring or assertiveness training or relaxation training) in ti,ab)
13. ((therapeutic communit* or motivational interview* or motivational enhance* or counseling or counselling or psychotherapy or
cognitive behavi*) in ti,ab)
14. ((work ethic or drug education or tasc or treatment accountability) in ti,ab)
15. ((asro or addressing substance or pasro or prisons addressing or acupuncture or shock or boot camp*) in ti,ab)
16. ((arrest referral* or diversion or dtto or dttos or drug treatment or carat or carats or counseling assessment or combined orders)
in ti,ab)
17. ((residential program* or residential scheme* or residential service*) in ti,ab)
18. ((syringe exchange or dual diagnosis or narcotics anonymous or self help or selfhelp or outreach or bail support) in ti,ab)
19. ((drug-free or drug free or peer support or evaluation* or urinalysis or drug testing or drug use screen* or rehabilitation or discrete
service* or discrete program*) in ti,ab)
20. ((aftercare or after care or brief solution or brief intervention* or 12 step* or twelve step* or minnesota program* or needle
exchange or nes) in ti,ab)
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21. ((trigger* or coping skills or anger management or group work or lifestyle modif* or high intensity training or resettlement or
throughcare) in ti,ab)
22. ((self management or interpersonal skills or social skills or basic skills or relapse prevent* or prevent* relapse or craving reduc* or
reduc* craving) in ti,ab)
24. ((rational-emotive or rational emotive or family relationship therap* or community reinforcement or self monitoring or goal
setting or self control training) in ti,ab)
25. #1 or #2
26. #3 or #4 or #5 or #6 or #7 or #8 or 9 or #10 or #11
27. #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24
28. 25 and #26 and #27
Appendix 10. SIGLE search strategy
SIGLE
1. ((reoffend* or reincarcerat* or recidivi* or ex-offend* or jail or jails or incarcerat* or secure facilit* or convict* or revocation or
inmate*) in ti,ab)
2. ((remand or prison* or offender* or criminal* or probation or court or courts or secure establishment*) in ti,ab
3. ((drug dependenc* or drug addict* or narcotics abuse* or narcotics use* or narcotics misuse* or narcotics addict*) in ti,ab
4. ((drug abuse* or drug misuse* or drug use*) in ti,ab
5. ((substance abuse* or substance misuse* or substance use*) in ti,ab
6. ((detox* or methadone maintenance or methadone prescri* or antagonist prescri* or dimorphine or naltrexone) in ti,ab
7. ((dependence disorder or drug involved) in ti,ab
8. ((amphetamine* abuse* or amphetamine* misuse* or amphetamine* use* or amphetamine* addict*) in ti,ab
9. ((cocaine abuse* or cocaine misuse* or cocaine use* or cocaine addict*) in ti,ab
10. ((crack abuse* or crack misuse* or crack use* or crack addict*) in ti,ab
11. ((heroin abuse* or heroin misuse* or heroin use* or heroin addict*) in ti,ab
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12. ((chemical dependenc* or opiate abuse* or opiate misuse* or opiate use* or opiate addict*) in ti,ab
13. #1 or #2
14. #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12
15. #13 and #14
Appendix 11. Criminal Justice Abstracts search strategy
CJA search
1. (substance abuse* or substance misuse* or substance use or substance users) in ti,ab,de
2. substance related in ti,ab,de
3. drug related in ti,ab,de
4. (drug dependenc* or drug abuse* or drug misuse* or drug use or drug users or drug addiction) in ti,ab,de
5. (narcotics use or narcotics users or narcotics abuse* or narcotics misuse* or chemical dependenc*) in ti,ab,de
6. (opiates or heroin or crack or cocaine or amphetamines or addict or addicts or addicted or dependence disorder* or drug involved)
in ti,ab,de
7. (designer drugs or street drugs or polydrug misuse* or polydrug abuse*) in ti,ab,de
8. #1 or #2 or #3 or #4 or #5 or #6 or #7
9. ((antagonist near prescri*) or diamorphine or naltrexone) in ti,ab,de
10. (therapeutic communit* or (motivational near interview*)) in ti,ab,de
11. (motivational near enhancement) in ti,ab,de
12. (counselling or counseling) in ti,ab,de
13. (psychotherap* or cognitive behav* or behav* therap* or (moral near training)) in ti,ab,de
14. (cognitive restructuring or (assertiveness near train*) or relaxation training) in ti,ab,de
15. (rational emotive or family relationship therap*) in ti,ab,de
16. (community reinforcement or self monitoring or goal setting or goalsetting) in ti,ab,de
89Interventions for drug-using offenders with co-occurring mental illness (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
17. (self control near training) in ti,ab,de
18. (self management) in ti,ab,de
19. (interpersonal skills near training) in ti,ab,de
20. ((social skills or basic skills) near training) in ti,ab,de
21. ((relapse near prevent*) or (craving near reduc*)) in ti,ab,de
22. (trigger* or coping skills or anger management or group work or (lifestyle near modif*)) in ti,ab,de
23. (high intensity training or resettlement or throughcare or aftercare or after care) in ti,ab,de
24. (brief solution* or brief intervention*) in ti,ab,de
25. (minnesota in ti,ab) in ti,ab,de
26. (12 step* or twelve step*) in ti,ab,de
27. (needle exchange or nes or syringe exchange) in ti,ab,de
28. (dual diagnosis or narcotics anonymous or self help or selfhelp or outreach) in ti,ab,de
29. (bail support or bail program* or arrest referral* or diversion or dtto* or drug treatment) in ti,ab,de
30. (carat or counselling assessment or counseling assessment) in ti,ab,de
31. (combined order* or drug free wing* or drug free environment* or peer support) in ti,ab,de
32. (user evaluations or urinalys* or urinanalys* or drug test* or rehab* or discrete service*) in ti,ab,de
33. (discrete program* or residential program* or residential scheme*) in ti,ab,de
34. (asro or addressing substance*) in ti,ab,de
35. (pasro or prisons addressing) in ti,ab,de
36. (acupuncture or shock or boot camp or boot camps or work ethic camp*) in ti,ab,de
37. (drug education or tasc or treatment accountability) in ti,ab,de
38. (detoxification or detox or methadone maintenance or (methadone near prescri*)) in ti,ab,de
39. #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26
or #27 or #28 or #29
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40. #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39
41. #39 or #40
42. #8 and #41
Appendix 12. National Research Register search strategy
NRR search
1. REMAND
2. PRISON*
3. OFFENDER*
4. ((CRIMINAL* or PROBATION) or COURT) or COURTS)
5. (SECURE next ESTABLISHMENT*)
6. REOFFEND*
7. REINCARCERAT*
8. RECIDIV*
9. EXOFFEND*
10. ((JAIL or JAILS) or INCARCERAT*)
11. (SECURE next FACILIT*)
12. (((CONVICT* or REVOCATION) or INMATE*) OR (HIGH next SECURITY))
13. PRISONERS:ME
14. LAW-ENFORCEMENT:ME
15. JURISPRUDENCE:ME
16. CRIME:ME
17. #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10
18. #11 or #12 or #13 or #14 or #15 or #16
91Interventions for drug-using offenders with co-occurring mental illness (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
19. #17 or #18
20. ((SUBSTANCE next ABUSE*) or (SUBSTANCE next MISUSE*)) OR (DRUG NEXTDEPENDENC*)) OR (DRUG NEXT
ABUSE*)) OR (DRUG NEXT MISUSE*)) OR (DRUG NEXT USE*)) OR (DRUG NEXT ADDICTION))
21. ((NARCOTICS or (CHEMICAL next DEPENDENC*)) OR (OPIATE NEXT ADDICT*)) OR (OPIATE NEXT DEPEN-
DENC*)) OR (OPIATE NEXT ABUSE*)) OR (OPIATE NEXT MISUSE*))
22. ((HEROIN next ADDICT*) or (HEROIN next DEPENDENC*)) OR (HEROIN NEXT MISUSE*)) OR (HEROIN NEXT
ABUSE*))
23. ((CRACK next ADDICT*) or (CRACK next DEPENDENC*)) OR (CRACK NEXT MISUSE*)) OR (CRACK NEXT
ABUSE*)) OR (CRACK NEXT USE*))
24. ((COCAINE next ADDICT*) or (COCAINE next DEPENDENC*)) OR (COCAINE NEXT MISUSE*)) OR (COCAINE
NEXT ABUSE*)) OR (COCAINE NEXT USE*))
25. ((AMPHETAMINE* next ADDICT*) or (AMPHETAMINE* next DEPENDENC*)) OR (AMPHETAMINE* NEXT MIS-
USE*)) OR (AMPHETAMINE* NEXT ABUSE*)) OR (AMPHETAMINE* NEXT USE*))
26. ((ADDICTS or (DEPENDENCE next DISORDER)) OR (DRUG NEXT INVOLVED))
27. (SUBSTANCE-RELATED and DISORDERS:ME)
28. SUBSTANCE-RELATED-DISORDERS:ME
29. AMPHETAMINE-ABUSE:ME
30. COCAINE-ABUSE:ME
31. MARIJUANA-ABUSE:ME
32. OPIOID-RELATED-DISORDERS:ME
33. PHENCYCLIDINE-ABUSE:ME
34. SUBSTANCE-ABUSE-INTRAVENOUS:ME
35. SUBSTANCE-WITHDRAWAL-SYNDROME:ME
36. (STREET next DRUGS)
38. STREET-DRUGS:ME
39. DESIGNER-DRUGS:ME
40. NARCOTICS:ME
41. (COCAINE:ME or AMPHETAMINES:ME)
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42. ANALGESICS-ADDICTIVE:ME
43. ANALGESICS-OPIOID:ME
44. PSYCHOTROPIC-DRUGS:ME
45. #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37
or #38 or #39 or #40 or #41 or #42 or #43 or #44
46. 19 and 45
Appendix 13. SPECTRA search strategy
SPECTRA search
1. {remand} or {prison} or {offender} or {criminal} or {probation} or {court} or {tribunal} or {secure establishment} or {secure facilit} or
{reoffend} or {reincarcerat} or {recidivi} or {ex-offender} or {jail} or {incarcerat} or {convict} or {felon} or {reconvict} or {high security}
or {law enforcement}
{remand} or {prison} or {offender} or {criminal} or {probation} or {court} or {tribunal} or {secure establishment} or {secure facilit} or
{reoffend} or {reincarcerat} or {recidivi} or {ex-offender} or {jail} or {incarcerat} or {convict} or {felon} or {reconvict} or {high security}
or {law enforcement}
2. {substance} or {dependenc} or {drug abuse} or {drug use} or {drug misuse} or {addict}
All indexed fields: {remand} or {prison} or {offender} or {criminal} or {probation} or {court} or {tribunal} or {secure establishment} or
{secure facilit} or {reoffend} or {reincarcerat} or {recidivi} or {ex-offender} or {jail} or {incarcerat} or {convict} or {felon} or {reconvict}
or {high security} or {law enforcement}
OR
All unindexed fields: {remand} or {prison} or {offender} or {criminal} or {probation} or {court} or {tribunal} or {secure establishment}
or {secure facilit} or {reoffend} or {reincarcerat} or {recidivi} or {ex-offender} or {jail} or {incarcerat} or {convict} or {felon} or {reconvict}
or {high security} or {law enforcement}
AND
All unindexed fields: {substance} or {dependenc} or {drug abuse} or {drug use} or {drug misuse} or {addict} or {narcotics} or {opiates}
or {heroin} or {crack} or {cocaine} or {amphetamines} or {drug involved} or {substance-related} or {amphetamine-related} or {cocaine-
related} or {marijuana} or {opioid} or {street drug} or {designer drug}
3. narcotics
4. opiates
5. heroin
6. {crack}
7. cocaine
8. amphetamines
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9. drug involved
10. substance-related
11. amphetamine-related
12. cocaine-related
13. marijuana
14. opioid
15. street drug
16. designer drug
17. 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16
18. 1 AND 17
Appendix 14. Criteria for assessing risk of bias
Item Judgement Description
1. Random sequence generation (selection
bias)
Low risk The investigators describe a random component in the sequence gener-
ation process such as: random number table; computer random num-
ber generator; coin tossing; shuffling cards or envelopes; throwing dice;
drawing of lots; minimisation
High risk The investigators describe a non-random component in the sequence
generation process such as: odd or even date of birth; date (or day) of
admission; hospital or clinic record number; alternation; judgement of
the clinician; results of a laboratory test or a series of tests; availability of
the intervention
Unclear risk Insufficient information about the sequence generation process to permit
judgement of low or high risk
2. Allocation concealment (selection bias) Low risk Investigators enrolling participants could not foresee assignment because
1 of the following, or an equivalent method, was used to conceal alloca-
tion: central allocation (including telephone, web-based, and pharmacy-
controlled, randomisation); sequentially numbered drug containers of
identical appearance; sequentially numbered, opaque, sealed envelopes
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High risk Investigators enrolling participants could possibly foresee assignments
because 1 of the following methods was used: open random allocation
schedule (e.g. a list of random numbers); assignment envelopes without
appropriate safeguards (e.g. if envelopes were unsealed or nonopaque or
not sequentially numbered); alternation or rotation; date of birth; case
record number; any other explicitly unconcealed procedure
Unclear risk Insufficient information to permit judgement of low or high risk. This
is usually the case if the method of concealment is not described or not
described in sufficient detail to allow a definite judgement
3. Blinding of participants and providers
(performance bias)
Objective outcomes
Low risk No blinding or incomplete blinding, but the review authors judge that
the outcome is not likely to be influenced by lack of blinding; blinding
of participants and key study personnel ensured, and unlikely that the
blinding could have been broken
4. Blinding of participants and providers
(performance bias)
Subjective outcomes
Low risk Blinding of participants and providers and unlikely that the blinding
could have been broken
High risk No blinding or incomplete blinding, and the outcome is likely to be
influenced by lack of blinding
Blinding of key study participants and personnel attempted, but likely
that the blinding could have been broken, and the outcome is likely to
be influenced by lack of blinding
Unclear risk Insufficient information to permit judgement of low or high risk
5. Blinding of outcome assessor (detection
bias)
Objective outcomes
Low risk Noblinding of outcome assessment, but the review authors judge that the
outcome measurement is not likely to be influenced by lack of blinding
Blinding of outcome assessment ensured, and unlikely that the blinding
could have been broken
6. Blinding of outcome assessor (detection
bias)
Subjective outcomes
Low risk Noblinding of outcome assessment, but the review authors judge that the
outcome measurement is not likely to be influenced by lack of blinding
Blinding of outcome assessment ensured, and unlikely that the blinding
could have been broken
High risk No blinding of outcome assessment, and the outcome measurement is
likely to be influenced by lack of blinding
Blinding of outcome assessment, but likely that the blinding could have
been broken, and the outcome measurement is likely to be influenced by
lack of blinding
Unclear risk Insufficient information to permit judgement of low or high risk
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7. Incomplete outcome data (attrition bias)
For all outcomes except retention in treat-
ment or drop-out
Low risk No missing outcome data
Reasons for missing outcome data unlikely to be related to true outcome
(for survival data, censoring unlikely to be introducing bias)
Missing outcome data balanced in numbers across intervention groups,
with similar reasons for missing data across groups
For dichotomous outcome data, the proportion of missing outcomes
comparedwith observed event risk not enough tohave a clinically relevant
impact on the intervention effect estimate
For continuous outcome data, plausible effect size (difference inmeans or
standardised difference in means) among missing outcomes not enough
to have a clinically relevant impact on observed effect size
Missing data have been imputed using appropriate methods
All randomised participants are reported/analysed in the group they were
allocated to by randomisation irrespective of non-compliance and co-
interventions (intention to treat)
High risk Reason for missing outcome data likely to be related to true outcome,
with either imbalance in numbers or reasons for missing data across
intervention groups
For dichotomous outcome data, the proportion of missing outcomes
compared with observed event risk enough to induce clinically relevant
bias in intervention effect estimate
For continuous outcome data, plausible effect size (difference in means
or standardised difference in means) among missing outcomes enough
to induce clinically relevant bias in observed effect size
’As-treated’ analysis done with substantial departure of the intervention
received from that assigned at randomisation
Unclear risk Insufficient information to permit judgement of low or high risk (e.g.
number randomised not stated, no reasons for missing data provided;
number of drop-out not reported for each group)
8. Selective reporting (reporting bias) Low risk The study protocol is available and all of the study’s pre-specified (primary
and secondary) outcomes that are of interest in the review have been
reported in the pre-specified way
The study protocol is not available, but it is clear that the published
reports include all expected outcomes, including those that were pre-
specified (convincing text of this nature may be uncommon)
High risk Not all of the study’s pre-specified primary outcomes have been reported
1 or more primary outcomes is reported using measurements, analysis
methods, or subsets of the data (e.g. subscales) that were not pre-specified
1 or more reported primary outcomes were not pre-specified (unless clear
justification for their reporting is provided, such as an unexpected adverse
effect)
1 or more outcomes of interest in the review are reported incompletely
so that they cannot be entered in a meta-analysis
The study report fails to include results for a key outcome that would be
expected to have been reported for such a study
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(Continued)
Unclear risk Insufficient information to permit judgement of low or high risk
9. Other bias * Low risk Evidence to suggest other problems identified with the study that might
threaten the validity of the random allocation, attrition or data integrity
and results of the trial
High risk Evidence to suggest that the trial might be underpowered/problems with
the random allocation process leading to potential self selection bias/
issues of analysis not conducted using intention-to-treat analysis or evi-
dence of missing data. Concerns of attrition and measurement error in-
cluding reliance on self report measures
Unclear risk Insufficient information to permit judgement of low or high risk
WH A T ’ S N E W
Last assessed as up-to-date: 31 May 2014.
Date Event Description
2 June 2015 Amended Amended byline
18 May 2015 New citation required but conclusions have not changed conclusions not changed
11 July 2014 New search has been performed This review has been update to May 2014. The process
has added an additional 3 trials bringing the total number
of trials for this review to 8 represented by 14 publications
H I S T O R Y
Review first published: Issue 1, 2014
Date Event Description
28 May 2012 New search has been performed This reviewhas beenupdated using searches to 21stMarch
2013. The review represents one in a family of four re-
views. The reviews cover pharmacological, non pharma-
cological and drug using female offenders. This review
of interventions with drug-using offenders with co-occur-
ring mental illness contains five randomised controlled
trials. The trials represent a total of 1,502 participants
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(Continued)
2 October 2011 New search has been performed The updated edit of this review produced a new document
with additional findings with searches up to 11th Novem-
ber 2011. Five new authors have been added to this ver-
sion of the review. These include Steven Duffy, Rachael
McCool, Matthew Neilson, Catherine Hewitt and Mar-
rissa Martyn-St James
1 July 2011 Amended Converted to new review format.
8 June 2011 New search has been performed Review has been substantially updated
19 May 2006 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
One review author (DF) constructed and conducted the searches. Three review authors (AEP, MN, RW) independently inspected titles
and abstracts identified by the search strategy. We obtained each potentially relevant study as a full article, and two review authors
independently assessed these for inclusion In the case of discordance, a third review author arbitrated. Where it was not possible to
evaluate the study because of language problems or missing information, we classified the study as ’translation/information required to
determine decision’ until we could obtain a translation or further details. Five review authors (AEP,MM-SJ, JMG, RW,MN) conducted
data extraction for the papers, and one review author (CG) conducted data extraction and a narrative summary of the cost-effectiveness
studies. Five review authors (MM-ST, MN, CH, RW, AEP) compiled and organised the results, and all eight review authors contributed
to the final draft text.
D E C L A R A T I O N S O F I N T E R E S T
Amanda E Perry have no interests to declare relating to this work
Matthew Neilson have no interests to declare relating to this work
Marrissa Martyn-St James have no interests to declare relating to this work
Julie M Glanville have no interests to declare relating to this work
Dave Fox have no interests to declare relating to this work
Rebecca Woodhouse have no interests to declare relating to this work
Catherine Hewitt have no interests to declare relating to this work
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S O U R C E S O F S U P P O R T
Internal sources
• Reviewer from Cochrane Drugs and Alcohol Group, Other.
A reviewer from the Drugs and Alcohol Group provided the researchers with the results of a search strategy for three databases
External sources
• The Department of Health funded the original review, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
None.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Case Management; Crime [prevention & control; statistics & numerical data]; Diagnosis, Dual (Psychiatry); Law Enforcement;Mental
Disorders [∗therapy]; Motivational Interviewing; Randomized Controlled Trials as Topic; Substance-Related Disorders [∗therapy];
Therapeutic Community
MeSH check words
Adolescent; Adult; Female; Humans; Male; Young Adult
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